Pharmaceutical compositions of kinase inhibitors

JP2023548855A5Active Publication Date: 2024-11-12EXELIXIS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526968
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-05
Filing Date
2021-11-04
Publication Date
2024-11-12
Estimated Expiration
2041-11-04

AI Technical Summary

Benefits of technology

【0006】 本発明は、化合物1、すなわち、以下の構造を有するN-(4-フルオロフェニル)-N-(4-((7-メトキシ-6-(メチルカルバモイル)キノリン-4-イル)オキシ)フェニル)シクロプロパン-1,1-ジカルボキサミド: 【化】 または薬学的に許容されるその塩の医薬組成物であって、化合物1が結晶固体である、医薬組成物を提供する。本明細書に開示される配合物は、他の形態と比較して製造性及び特性が改善されていることが期せずして判明した。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022098828000001
    Figure 2022098828000001
  • Figure 2022098828000002
    Figure 2022098828000002
Patent Text Reader

Abstract

The present invention relates to pharmaceutical compositions of Compound 1, a c-Met inhibitor. The present invention also relates to methods of using the pharmaceutical compositions to treat diseases, disorders, or syndromes mediated at least in part by modulating the in vivo activity of protein kinases, and to processes for making the pharmaceutical compositions. In another aspect, the present invention relates to a method for inhibiting a protein kinase, comprising contacting the protein kinase with a pharmaceutical composition of Compound 1 in a crystalline form or crystalline salt form as described herein. In yet another aspect, the present invention relates to a process for preparing a pharmaceutical composition of Compound 1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 110,124, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to pharmaceutical compositions of the free base or pharmaceutically acceptable salts of Compound 1. The present invention also relates to pharmaceutical formulations of crystalline salt forms of Compound 1. The present invention further relates to methods of treating diseases, disorders, or syndromes mediated at least in part by modulating the in vivo activity of protein kinases with Compound 1 as a pharmaceutical composition. [Background technology]

[0003] Human Axl belongs to the TAM (Tyro3, ​​Axl, and Mer) subfamily of Mer-containing receptor tyrosine kinases. TAM kinases are characterized by an extracellular ligand-binding domain consisting of two immunoglobulin-like domains and two fibronectin type III domains. Axl is overexpressed in many tumor cell types and was originally cloned from a patient with chronic myeloid leukemia. Overexpression of Axl exhibits transforming potential. Axl signaling is thought to drive tumor growth through activation of proliferative and anti-apoptotic signaling pathways. Axl has been associated with cancers such as lung cancer, myeloid leukemia, uterine cancer, ovarian cancer, glioma, melanoma, thyroid cancer, renal cell carcinoma, osteosarcoma, gastric cancer, prostate cancer, and breast cancer. Overexpression of Axl results in a poor prognosis for patients with the indicated cancers.

[0004] Activation of Mer, like Axl, transduces downstream signaling pathways that lead to tumor growth and activation. Mer binds to ligands, such as the soluble protein Gas-6. Binding of Gas-6 to Mer induces autophosphorylation of Mer at its intracellular domain, resulting in downstream signal activation. Overexpression of Mer in cancer cells leads to increased metastasis, possibly due to the generation of soluble Mer ectodomain protein as a decoy receptor. Tumor cells secrete a soluble form of the extracellular Mer receptor, which reduces the ability of soluble Gas-6 ligand to activate Mer on endothelial cells, leading to cancer progression.

[0005] Therefore, there is a need for compounds that inhibit TAM receptor tyrosine kinases such as Axl and Mer for the treatment of selected cancers. Summary of the Invention [Means for solving the problem]

[0006] The present invention provides compound 1, i.e., N-(4-fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide, having the following structure: [ka] or a pharmaceutically acceptable salt thereof, wherein Compound 1 is a crystalline solid. The formulations disclosed herein have unexpectedly been found to have improved manufacturability and properties compared to other forms.

[0007] Compound 1 is defined in WO2019 / 148044, which is incorporated herein by reference in its entirety. Various crystalline solid forms and crystalline salts of Compound 1 are disclosed in WO2020 / 123800, which is incorporated herein by reference in its entirety.

[0008] In one embodiment, the pharmaceutical composition is suitable for oral administration. a. Compound 1 or a pharmaceutically acceptable salt thereof; b. one or more diluents; c. one or more binders; d. one or more disintegrants; e. one or more glidants; f. one or more lubricants, and optionally, g. film coating.

[0009] Compound 1 may be present in pharmaceutical compositions as a crystalline solid of the free base or as a crystalline pharmaceutically acceptable salt. For the avoidance of doubt, reference to "Compound 1" includes these crystalline free base forms and crystalline salt forms, unless otherwise specified.

[0010] In one embodiment of this aspect, Compound 1 is a crystalline solid form characterized as Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form K, Form O, or Form Q.

[0011] In another embodiment of these aspects, Compound 1 is a crystalline HCl salt of Compound 1.

[0012] In another embodiment of these aspects, Compound 1 is a crystalline fumarate salt of Compound 1, or a hydrate or solvate thereof.

[0013] In another embodiment, Compound 1 is a crystalline phosphate salt of Compound 1, or a hydrate or solvate thereof.

[0014] In yet another aspect, the present invention relates to a method for treating a disease, disorder, or syndrome mediated at least in part by modulating the in vivo activity of a protein kinase, comprising administering to a subject in need of treatment for the disease, disorder, or syndrome a pharmaceutical composition of Compound 1, or a pharmaceutically acceptable salt thereof.

[0015] In yet another aspect, the present invention relates to a method of treating cancer, comprising administering to a subject in need of cancer treatment a pharmaceutical composition of Compound 1, or a pharmaceutically acceptable salt thereof.

[0016] In another aspect, the present invention relates to a method for inhibiting a protein kinase, comprising contacting the protein kinase with a pharmaceutical composition of Compound 1 in a crystalline form or crystalline salt form described herein.

[0017] In yet another aspect, the present invention relates to a process for preparing a pharmaceutical composition of Compound 1. DETAILED DESCRIPTION OF THE INVENTION

[0018] Definitions, Abbreviations, and Acronyms

[0019] [Table 1]

[0020] [Table 2]

[0021] [Table 3]

[0022] [Table 4]

[0023] As used herein, the following definitions shall apply unless otherwise stated.

[0024] For purposes of this invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 95th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry," 2000, which is incorporated herein by reference in its entirety. nd Ed., Thomas Sorrell, University Science Books, Sausalito: 2006, and “March's Advanced Organic Chemistry”, 7th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2013.

[0025] As used herein, the term "about," when referring to a numerical value or range, allows for a degree of variation of the value or range, for example, within 10%, 5%, 4%, 3%, 2%, 1%, or 0.5% of the stated value or boundary of the stated range. The stated value may be the dose, amount, or weight percent of each component of the composition or dosage form.

[0026] As used herein, the term "low / limited / significant moisture absorption" refers to a material that exhibits a water absorption rate of <0.5 / <2.0 / ≧2.0 wt % over a specified RH range.

[0027] As used herein, the term "stoichiometric hydrate" refers to a crystalline material having a defined water content over an extended RH range. Common stoichiometric hydrates are hemihydrate, monohydrate, sesquihydrate, dihydrate, etc.

[0028] As used herein, the term "variable hydrate" refers to a crystalline material that has a variable water content over an extended RH range.

[0029] As used herein, the chemical term "form" refers to a compound or salt thereof that consists of a single phase.

[0030] As used herein, the terms "low / limited / medium / good / high solubility" refer to substances with a solubility of <1 / 1-20 / 20-100 / 100-200 / >200 mg / mL.

[0031] As used herein, the term "disordered crystalline" refers to a material that produces an XRPD pattern with broad peaks (relative to the instrumental peak width) and / or strong diffuse scattering across the peaks. Disordered materials are: 1) Microcrystals, 2) Crystals with a high defect density, 3) a mixture of crystalline and X-ray amorphous phases, or 4) A combination of the above.

[0032] As used herein, the term "insufficient signal" means that spectral analysis of a sample produced a spectrum or pattern (output) that had insufficient signal above the expected background noise.

[0033] As used herein, the term "single crystalline phase" refers to an XRPD pattern that is determined to contain evidence of a single crystalline morphology because the Bragg peaks are indexed with a single unit cell. Indexing is the process of assigning Miller index labels to each peak in a diffraction pattern. The size and shape of the crystalline unit cell are also determined during the indexing process.

[0034] As used herein, the term "slurry" refers to a suspension prepared by adding sufficient solids to a given solvent at ambient conditions so that undissolved solids are present. A typical slurry involves agitation (typically by stirring or shaking) in a sealed container at a given temperature for an extended period of time, also known as "slurrying." Typically, the solids are recovered after a given time using methods described herein.

[0035] As used herein, the terms "X-ray amorphous" or "amorphous" refer to a material in which there is diffuse scattering in the XRPD pattern, but no evidence of Bragg peaks.

[0036] As used herein, the term "crystalline" refers to a compound in the solid state that exhibits a periodic, repeating, three-dimensional internal arrangement of atoms, ions, or molecules characteristic of a crystal, e.g., arranged in a fixed geometric pattern or lattice with rigid long-range order. The term crystalline does not necessarily mean that the compound exists as a crystal, but rather that it has such a crystalline internal structural arrangement. A compound that is crystalline will produce an XRPD pattern that exhibits sharp peaks (similar to instrumental peak widths) and weak diffuse scattering relative to the peaks.

[0037] As used herein, the term "substantially crystalline" refers to a solid material that is primarily arranged in a fixed geometric pattern or lattice with rigid long-range order. For example, a substantially crystalline substance has a crystallinity of greater than about 85% (e.g., greater than about 90% crystallinity, greater than about 95% crystallinity, or greater than about 99% crystallinity or about 100%). It should also be noted that the term "substantially crystalline" includes the descriptor "crystalline" as defined in the previous paragraph.

[0038] A "patient" for purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus, the present methods are applicable to both human therapy and veterinary applications. In preferred embodiments, the patient is a mammal, and in most preferred embodiments, the patient is human. Examples of preferred mammals include mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, and primates.

[0039] "Kinase-dependent diseases or conditions" refer to pathological conditions that depend on the activity of one or more kinases. Kinases are directly or indirectly involved in signal transduction pathways for a wide range of cellular activities, including proliferation, adhesion, migration, differentiation, and invasion. Diseases associated with kinase activity include pathological angiogenesis that supports tumor growth, solid tumor growth, and is associated with other diseases involving excessive local angiogenesis, such as ocular diseases (e.g., diabetic retinopathy, age-related macular degeneration) and inflammation (e.g., psoriasis, rheumatoid arthritis).

[0040] A "therapeutically effective amount" is an amount of a crystalline form or crystalline salt form of the invention that, when administered to a patient, ameliorates the symptoms of the disease. The amount of a crystalline form or crystalline salt form of the invention that constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, the age of the patient being treated, etc. A therapeutically effective amount can be routinely determined by one of ordinary skill in the art in light of their own knowledge and this disclosure.

[0041] The phrase "pharmaceutically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problem or complication commensurate with a reasonable benefit / risk ratio.

[0042] As used herein, the phrase "pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients are generally safe, non-toxic, and not biologically or otherwise undesirable, and include excipients that are acceptable for veterinary and human pharmaceutical use. In one embodiment, each component is "pharmaceutically acceptable" as defined herein. For example, Remington:The Science and Practice of Pharmacy,21st ed.Lippincott Williams & Wilkins:Philadelphia,Pa.,2005;Handbook of'Pharmaceutical Excipients,6th ed.;Rowe et al,Eds.;The Pharmaceutical Press and the American Pharmaceutical Association:2009;Handbook of Pharmaceutical Additives,3rd ed.;Ash and Ash Eds.;Gower Publishing Company: 2007; Pharmaceutical Pref or mulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009.

[0043] As used herein, the term "concentration" refers to the weight of Compound 1 as a free base equivalent in a unit dosage form of a pharmaceutical composition. For example, a tablet containing 22.20 mg of Compound 1 hemifumarate is a 20 mg dosage strength tablet, since 22.20 mg of Compound 1 hemifumarate is equivalent to 20 mg of Compound 1 free base. Similarly, a tablet containing 44.40 mg of Compound 1 hemifumarate is a 40 mg strength tablet.

[0044] As used herein, the term "concurrently" means at the same time. For example, if two therapeutic regimens are administered to a patient concurrently, they are administered at the same time. It is understood that two therapeutic regimens administered concurrently does not necessarily mean that the actual delivery of the two drugs is administered at the same time, as each regimen may require a different dosing schedule and / or a different delivery form.

[0045] "Cancer" includes, but is not limited to, heart: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; head and neck: squamous cell carcinoma of the head and neck, laryngeal and hypopharyngeal carcinoma, nasal cavity and paranasal sinus carcinoma, nasopharyngeal carcinoma, salivary gland carcinoma, oral and oropharyngeal carcinoma; lung: bronchogenic carcinoma (squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma, non-small cell lung carcinoma), alveolar (bronchiolar) carcinoma, lung Alveolar sarcoma, alveolar soft part sarcoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Colon: colorectal carcinoma, adenocarcinoma, gastrointestinal stromal tumor, lymphoma, carcinoid, Turcot's syndrome; Gastrointestinal: gastric carcinoma, gastroesophageal junction adenocarcinoma, esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), colon (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); breast cancer: metastatic breast cancer, ductal carcinoma in situ, invasive ductal carcinoma, tubular adenocarcinoma, medullary carcinoma, mucinous carcinoma, lobular carcinoma in situ, triple-negative breast cancer; genitourinary system: kidney (adenocarcinoma, Wilms' tumor [nephroblastoma], lymphoma, leukemia, renal cell carcinoma, metastatic renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, urothelial carcinoma), prostate (adenocarcinoma, sarcoma, castration-resistant prostate cancer, bone metastasis, bone metastasis associated with castration-resistant prostate cancer), testis (seminoma, teratoma, embryonal carcinoma) , teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenocarcinoma, lipoma), clear cell carcinoma, papillary carcinoma; penile cancer, penile squamous cell carcinoma; liver: hepatocellular carcinoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell chondroma, osteochondroma (osteochondroid exostosis), benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor; thyroid: medullary thyroid carcinoma, differentiated thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma, Hurthle cell carcinoma, and anaplastic thyroid carcinoma;Nervous system: skull (osteoma, hemangioma, granuloma, xanthomas, osteitis deformans), meningiomas (meningiomas, meningeal sarcomas, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, embryonal tumor [pineal tumor], glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibromas, meningiomas, gliomas, sarcomas); NF1, neurofibromatosis, plexiform neurofibromas; gynecology: uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovaries (ovarian cancer [serous cyst adenocarcinoma]) carcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granuloma-cerebellar cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma), fallopian tube (carcinoma); blood: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), myelofibrosis, polycythemia vera The term "cancerous cell" refers to any physiological condition in a mammal characterized by uncontrolled cell proliferation, particularly a cell proliferative disorder, including: thyroid cancer, essential thrombocythemia, Hodgkin's disease, non-Hodgkin's lymphoma; skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, lentil dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal gland: neuroblastoma. Thus, the term "cancerous cell" as used herein includes cells with any one of the above-identified conditions. In some embodiments, the compounds or combinations disclosed herein can be used to treat diseases including HIV, sickle cell disease, graft-versus-host disease, acute graft-versus-host disease, chronic graft-versus-host disease, and sickle cell anemia. In some embodiments, the cancer is clear cell renal cell carcinoma, non-clear cell carcinoma, non-clear cell renal cell carcinoma, salivary gland carcinoma, penile squamous cell carcinoma, neuroendocrine tumor, adrenocortical carcinoma, or Merkel cell carcinoma.

[0046] The term "treat" or "treatment" refers to any indication of success or improvement in the progression, severity and / or duration of a disease, condition, or state, and includes any objective or subjective parameter, such as remission, remission, disappearance of symptoms or making the injury, condition, or state tolerable to the patient, slowing the rate of degeneration or decline, making the end point of degeneration less debilitating, or improving the physical or mental well-being of the patient.

[0047] The term "enhance" refers to an increase or improvement in the function or activity of a protein or cell after administration or contact with a combination described herein compared to the protein or cell before such administration or contact.

[0048] The term "administering" refers to the act of delivering a combination or composition described herein to a subject by a route such as oral, mucosal, topical, suppository, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, or subcutaneous administration. Parenteral administration includes, for example, intravenous, intramuscular, intraarteriolar, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. Administration generally occurs after the onset of a disease, disorder, or condition, or a symptom thereof, but in certain cases can occur before the onset of a disease, disorder, or condition, or a symptom thereof (e.g., administration to a patient predisposed to such a disease, disorder, or condition).

[0049] The term "co-administration" refers to the administration of two or more agents (e.g., one described herein in combination with another active agent, such as an anti-cancer agent described herein). The timing of co-administration depends in part on the combination and composition administered and can include, for example, administration simultaneously with, immediately before, or immediately after the administration of one or more additional therapies, such as chemotherapy, hormonal therapy, radiation therapy, or immunotherapy. The compounds of the present invention may be administered to a patient alone or simultaneously. Co-administration is intended to include simultaneous or sequential administration of compounds individually or in combination (multiple compounds or agents). Thus, formulations can also be combined with other active agents, if desired (e.g., to reduce metabolic degradation). The compounds described herein can be used in combination with other active agents known to be useful in the treatment of cancer.

[0050] The term "anti-cancer agent" is used according to its plain and ordinary meaning to refer to a composition having anti-tumor properties or the ability to inhibit cell growth or proliferation. In embodiments, the anti-cancer agent is a chemotherapeutic agent. In embodiments, the anti-cancer agent is an agent identified herein that has utility in methods of treating cancer. In some embodiments, the anti-cancer agent is an agent approved by the FDA or a similar regulatory agency outside the United States for the treatment of cancer.

[0051] The terms "chemotherapeutic" or "chemotherapeutic agent" are used according to their plain and ordinary meaning to refer to a chemical composition or compound having anti-tumor properties or the ability to inhibit cell growth or proliferation. "Chemotherapy" refers to a treatment or regimen that includes the administration of a chemotherapeutic or anti-cancer agent as described herein.

[0052] In general, the nomenclature used in this application is based on the naming conventions adopted by the International Union of Pure and Applied Chemistry (IUPAC). The chemical structures shown herein were generated using CHEMDRAW®. Any open valence appearing on a carbon, oxygen, or nitrogen atom in the structures herein indicates the presence of a hydrogen atom.

[0053] Embodiment Pharmaceutical Composition The present disclosure relates to pharmaceutical compositions suitable for oral administration comprising Compound I or a pharmaceutically acceptable salt thereof.

[0054] In one aspect, the pharmaceutical composition comprises: a. Compound 1; b. one or more diluents; c. one or more binders; d. one or more disintegrants; e. one or more glidants; f. one or more lubricants, and optionally, g. film coating.

[0055] Compound 1 has the following structure: [ka] Also known as 1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide or N'-(4-fluorophenyl)-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide. As used herein, Compound 1 includes the crystalline free base solid form of Compound 1, as well as crystalline salt forms of Compound 1, or a salt, solvate, or hydrate thereof.

[0056] Examples of pharmaceutically acceptable diluents, binders, disintegrants, glidants, lubricants, and coatings can be found in references readily available to those skilled in the art, such as Handbook of Pharmaceutical Excipients, 7th Ed. R. Rowe, P. Sheskey, and S. Owen, Eds., 2012, Pharmaceutical Press, London England., and Remington, The Science and Practice of Pharmacy, 21 st It is described in detail by Ed. P. Gerbino, Ed., Lipincott Williams & Wilkins, Philadelphia, PA.

[0057] The diluent may be any diluent known to those skilled in the art. In one embodiment, the diluent is an inorganic diluent, a polysaccharide, a monosaccharide or disaccharide, or a sugar alcohol. In another embodiment, the diluent comprises lactose, microcrystalline cellulose, starch, corn starch, croscarmellose sodium, or a mixture thereof.

[0058] The binder may be any binder known to those skilled in the art. Suitable binders include sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate (PVP / VA) copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, or a mixture thereof. In another embodiment, the binder is PVP. In another embodiment, the binder is hydroxypropyl cellulose.

[0059] The disintegrant may be any disintegrant known to those skilled in the art. Suitable disintegrants include croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, sodium starch glycolate, or mixtures thereof.

[0060] The glidant can be any glidant known to those skilled in the art.Suitable glidants include starch, cornstarch, silicon dioxide, colloidal silicon dioxide, or a mixture thereof.In another embodiment, the glidant is silicon dioxide.In another embodiment, the glidant is colloidal silicon dioxide.

[0061] The lubricant can be any lubricant known to those skilled in the art, hi another embodiment, the lubricant is stearic acid or magnesium stearate.

[0062] In these and other embodiments, the film coating can be any film coating known to those skilled in the art, and such coatings are widely available commercially, including coatings that include the component.

[0063] As used herein, the terms "film coating" and "film-coated" refer to a mixture of pharmaceutically acceptable excipients typically applied to compressed tablets, beads, granules, or particles of an active ingredient that are compressed into a tablet. It will be understood that the coating selected must be compatible with the active agent. It will further be understood by those skilled in the art that methods for engineering a coating to disintegrate in the stomach are well known by selecting the excipients that comprise the coating, their type, and / or its thickness.

[0064] Suitable polymers for film coating according to the present invention are soluble at a pH of about 1.2 to about 5, such as, for example, hydroxypropylmethylcellulose (HPMC) alone and / or in combination with hydroxypropylcellulose (HPC), carboxymethylcellulose, methylcellulose, ethylcellulose, acrylic resins, and polyvinylpyrrolidone and gelatin, or other commercially available film coating formulations such as Dri-Klear® (Crompton & Knowles Corp., Mahwah, NJ) or Opadry® (Colorcon, West Point Pa).

[0065] In another embodiment, the film coating is comprised of a commercially available film coating product designed for aqueous film coating, containing a water-soluble film-forming resin, hydroxypropyl methylcellulose, and polyethylene glycol (or other suitable plasticizer, such as propylene glycol or glycerin), and optionally containing titanium dioxide (or other colorant or opacifier). Such a product is commercially available under the trade name Opadry® II Blue (Colorcon, West Point, PA).

[0066] A suitable blend for the coating may include 0 to about 20% w / w titanium dioxide or colorant, about 5 to about 95% w / w hydroxypropyl methylcellulose, and 0 to about 25% w / w polyethylene glycol. In one embodiment, the coating includes 10.5% non-aqueous additives, of which 7.5% is Opadry®, based on the total weight of the coating.

[0067] The coating may further comprise flavoring agents, taste masking agents, and salivating agents as defined above, for example in small amounts such as, for example, 0.1-1.0% w / w, preferably 0.1-0.4% w / w, based on the weight of the total blend of the coating. Preferred flavoring agents and / or taste masking agents may be selected from the group of agents defined above.

[0068] The amount of coating applied to a tablet is generally in the range of about 1.0% to about 6.0% weight gain, preferably 2.0% to 5.0% weight gain, which means the weight gain of the coated tablet relative to the weight of the uncoated tablet.

[0069] In one embodiment, the pharmaceutical composition comprises: a. Compound 1 or a pharmaceutically acceptable salt thereof; b. one or more diluents selected from the group consisting of inorganic diluents, polysaccharides, mono- or disaccharides, sugar alcohols, and mixtures thereof; c. one or more binders selected from the group consisting of sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate (PVP / VA) copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, and mixtures thereof; d. one or more disintegrants selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, starch, sodium starch glycolate, and mixtures thereof; e. one or more glidants; f. one or more lubricants, and optionally, g. film coating.

[0070] In one embodiment, the pharmaceutical composition comprises: a. Compound 1 or a pharmaceutically acceptable salt thereof; b. one or more diluents selected from the group consisting of inorganic diluents, polysaccharides, mono- or disaccharides, and sugar alcohols; c. one or more binders selected from the group consisting of sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate (PVP / VA) copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and ethyl cellulose; d. one or more disintegrants selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, starch, and sodium starch glycolate; e. one or more glidants; f. one or more lubricants, and optionally, g. film coating.

[0071] In one embodiment, the pharmaceutical composition comprises: a. Compound 1 or a pharmaceutically acceptable salt thereof; b. one or more diluents selected from the group consisting of inorganic diluents, polysaccharides, mono- or disaccharides, and sugar alcohols; c. one or more binders selected from the group consisting of sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate (PVP / VA) copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and ethyl cellulose; d. one or more disintegrants selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and sodium starch glycolate; e. silicon dioxide; f. one or more lubricants, and optionally, g. film coating.

[0072] In one embodiment, the pharmaceutical composition comprises: a. Compound 1 or a pharmaceutically acceptable salt thereof; b. one or more diluents selected from the group consisting of inorganic diluents, polysaccharides, mono- or disaccharides, and sugar alcohols; c. one or more binders selected from the group consisting of sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate (PVP / VA) copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and ethyl cellulose; d. one or more disintegrants selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and sodium starch glycolate; e. silicon dioxide; f. stearic acid or magnesium stearate, and optionally g. film coating.

[0073] In certain embodiments, the pharmaceutical compositions of the present disclosure can be compacted into a unit dosage form such as a tablet or caplet, or can be incorporated into a unit dosage form, such as a capsule. In further embodiments, the pharmaceutical compositions of the present disclosure can be formulated for administration as a powder or suspension. For example, a pharmaceutical formulation of the present disclosure comprising a powder can be sprinkled or mixed into a semi-solid carrier, such as applesauce or another food, for administration to a subject. The powder can also be added to a liquid carrier suitable for administration to a subject to form a suspension, such as an aqueous solution of about 2% w / v hydroxypropyl cellulose and about 0.1% w / v polysorbate 80, or an aqueous solution of about 0.2% hydroxypropyl cellulose and 0.1% Tween® 80.

[0074] In one embodiment, the dosage form of the present disclosure comprises a tablet containing about 5 mg to about 200 mg (free base equivalent), about 10 mg to about 150 mg (free base equivalent), about 15 mg to about 120 mg (free base equivalent), or about 20 mg to about 100 mg (free base equivalent) of Compound 1 or a pharmaceutically acceptable salt thereof.

[0075] In one embodiment, the dosage form of the present disclosure comprises a capsule containing about 5 mg to about 200 mg (free base equivalent), about 10 mg to about 150 mg (free base equivalent), about 15 mg to about 120 mg (free base equivalent), or about 20 mg to about 100 mg (free base equivalent) of Compound 1 or a pharmaceutically acceptable salt thereof.

[0076] In one embodiment, the dosage form of the disclosure comprises a tablet containing, for example, about (free base equivalent) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In one embodiment, the dosage form of the disclosure comprises a tablet containing, for example, about (free base equivalent) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, or 200 mg of Compound 1 or a pharmaceutically acceptable salt thereof. Other embodiments include capsules with a concentration of, for example, about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg. In one embodiment, the dosage form of the disclosure comprises a capsule containing about (free base equivalent) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, or 200 mg of Compound 1 or a pharmaceutically acceptable salt thereof. In a further embodiment, the dosage form of the disclosure is a tablet containing Compound 1 or a pharmaceutically acceptable salt thereof in a concentration of, for example, about 20 mg, 40 mg, 60 mg, 80 mg, or 100 mg. In a further embodiment, the dosage form of the disclosure is a tablet containing Compound 1 or a pharmaceutically acceptable salt thereof, for example, in a concentration of about 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, or 120 mg. In another embodiment, the dosage form of the disclosure is a capsule containing Compound 1 or a pharmaceutically acceptable salt thereof, for example, in a concentration of about 20 mg, 40 mg, 60 mg, 80 mg, or 100 mg.In further embodiments, the dosage form of the disclosure is a capsule containing Compound 1 or a pharmaceutically acceptable salt thereof, for example, in a concentration of about 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, or 120 mg.

[0077] Suitable methods for formulating the pharmaceutical compositions of the present disclosure into tablets are well known in the art and may include mixing the active ingredient and stabilizing polymer with one or more pharmaceutically acceptable tableting excipients and compressing the mixture into tablets, for example, by tablet press. The amount and nature of the tableting excipients used can be readily selected based on the desired tablet characteristics, such as size, hardness, friability, etc. Tablets containing the pharmaceutical compositions of the present disclosure can also be coated with a film coating, such as the Opadry® coating sold by Colorcon (West Point PA), or with an enteric coating designed to prevent dissolution of the tablet until it has passed through the stomach and / or upper intestine. Suitable tablet coatings and methods for applying them are well known in the art.

[0078] Suitable methods for formulating the pharmaceutical compositions of the present disclosure into capsules are also well known in the art and may include mixing the active ingredient and stabilizing polymer with one or more pharmaceutically acceptable capsule excipients and filling the mixture into a capsule. In one embodiment, the pharmaceutical formulation of the present disclosure (with or without additional excipients) can be filled into a capsule, such as a hard gelatin capsule. The hard gelatin capsule can be any suitable size, such as, for example, size "0," "0EL," "3," or "4." For example, in one embodiment, capsules of the present disclosure having a dose strength of 20 mg of Compound 1 can be filled into a size 4 hard gelatin capsule, with a target capsule fill weight of 100 mg. In another embodiment, capsules of the present disclosure having a dose strength of 100 mg of active ingredient can be filled into a size 0EL hard gelatin capsule, with a target capsule fill weight of 400 mg.

[0079] In one embodiment of the pharmaceutical composition, Compound 1 may be present at at least about 1% to about 99% w / w. In another embodiment, Compound 1 may be present at at least about 10% to about 90% w / w. In another embodiment, Compound 1 may be present at at least about 20% to about 70% w / w. In another embodiment, Compound 1 may be present at at least about 10% to about 50% w / w. In another embodiment, Compound 1 may be present at at least about 20% to about 40% w / w. In another embodiment, Compound 1 may be present at at least about 25% to about 35% w / w. In another embodiment, Compound 1 is present in the pharmaceutical composition at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% w / w Or it may be present at 100% weight / weight (w / w).

[0080] In some embodiments, the pharmaceutical compositions of the present disclosure are stable when exposed to predetermined conditions for a predetermined period of time. For example, the pharmaceutical formulations of the present disclosure can be stored, for example, in open or closed containers, at various predetermined temperatures and relative humidities for a specified or predetermined period of time. In some embodiments, the pharmaceutical compositions of the present disclosure remain stable at temperatures of at least about 0.5, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% relative humidity. Stable upon storage for 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 20, 25, 30, 35, 40, 45, 48, 50, 51, 52, 53, 55 or 60 hours, 1 week, 2 weeks, 3 weeks or 4 weeks; or 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 12 months.

[0081] In certain embodiments, the pharmaceutical compositions of the present disclosure are stable when stored in an open or closed container at about 30° C. and about 90% relative humidity for at least about 20 hours; at about 40° C. and about 60% relative humidity for at least about 1 week, 2 weeks, or 3 weeks; at about 40° C. and about 75% relative humidity for at least about 1 week, 2 weeks, or 3 weeks; at about 25° C. and about 60% relative humidity for at least about 1 month; at about 40° C. and about 75% relative humidity for at least about 1 month; at about 25° C. and about 75% relative humidity for at least about 3 months; or at 5° C. and any relative humidity. In some embodiments, "storage in an open container" means that the container is opened twice daily but otherwise remains closed for a given period of time, e.g., up to 4 weeks.

[0082] In another embodiment, a pharmaceutical composition comprising Compound 1 is stable when stored in an open or closed container at about 30°C and about 90% relative humidity for at least about 20 hours; at about 40°C and about 60% relative humidity for at least about 1 week, 2 weeks, or 3 weeks; at about 4°C and about 75% relative humidity for at least about 1 week, 2 weeks, or 3 weeks; at about 25°C and about 60% relative humidity for at least about 1 month; at about 40°C and about 75% relative humidity for at least about 1 month; at about 25°C and about 75% relative humidity for at least about 3 months; or at 5°C and any relative humidity.

[0083] In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 25° C. and about 60% relative humidity for at least about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months. In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 25° C. and about 60% relative humidity with a total purity of less than 0.1% for at least 1 month, 2 months, or 3 months. In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 25° C. and about 60% relative humidity with a total purity of less than 0.5% for at least 6 months. In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 25° C. and about 60% relative humidity with a total purity of less than 0.5% for at least 12 months.

[0084] In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 40° C. and about 75% relative humidity for at least about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months. In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 40° C. and about 75% relative humidity with a total purity of less than 0.1% for at least 1 month, 2 months, or 3 months. In another embodiment, a pharmaceutical composition comprising Compound 1 is stable upon storage in an open or closed container at about 40° C. and about 75% relative humidity with a total purity of less than 0.5% for at least 6 months.

[0085] The stability of the pharmaceutical compositions of the present disclosure can also be measured by testing other physical properties, such as by testing the dissolution of the pharmaceutical composition at the end of a predetermined time period after exposure to predetermined conditions, such as temperature and relative humidity. Suitable methods for measuring the dissolution profile of the pharmaceutical composition are well known in the art. Exemplary methods for measuring the dissolution profile of the pharmaceutical composition are, for example, either a basket dissolution test or a paddle dissolution test in simulated gastric fluid.

[0086] In one embodiment, a pharmaceutical composition comprising Compound 1 exhibits a 5 minute dissolution of 25%, 30%, 40%, or 50% after storage in an open or closed container at about 25° C. and about 60% relative humidity for at least about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits a 5 minute dissolution of greater than 50% after storage in an open or closed container at about 25° C. and about 60% relative humidity for at least about 1, 2, 3, 6, 7, or 12 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits greater than 70% dissolution at 10 minutes after storage in an open or sealed container at about 25° C. and about 60% relative humidity for at least about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits greater than 90% dissolution at 45 minutes after storage in an open or sealed container at about 25° C. and about 60% relative humidity for at least about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits greater than 95% dissolution at 75 minutes after storage in an open or closed container at about 25° C. and about 60% relative humidity for at least about 0 months, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

[0087] In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits a 5 minute dissolution of greater than 25%, 30%, 40%, or 50% after storage in an open or sealed container at about 40° C. and about 75% relative humidity for at least about 0, 1, 2, 3, 4, 5, or 6 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits a 10 minute dissolution of greater than 40%, 50%, 60%, or 70% after storage in an open or sealed container at about 40° C. and about 75% relative humidity for at least about 0, 1, 2, 3, 4, 5, or 6 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits a 45 minute dissolution of greater than 70%, 80%, or 90% after storage in an open or sealed container at about 40° C. and about 75% relative humidity for at least about 0, 1, 2, 3, 4, 5, or 6 months. In another embodiment, a pharmaceutical composition comprising Compound 1 exhibits greater than 90% or 95% dissolution at 75 minutes after storage in an open or closed container at about 40° C. and about 75% relative humidity for at least about 0 months, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.

[0088] In certain embodiments, pharmaceutical compositions of the present disclosure include tablets, capsules, sachets, powders, suspensions, suppositories, etc. In such dosage forms of the present disclosure, the amount of active ingredient comprising the dosage form can be any suitable amount, for example, about 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, or 100 mg per unit dosage form. In certain embodiments, dosage forms of the present disclosure include about 25 mg, 50 mg, 75 mg, 80 mg, or 100 mg of active ingredient, e.g., Compound 1, per dosage form.

[0089] Although exemplary amounts or ranges of Compound 1 and other pharmaceutical composition components are provided, the pharmaceutical compositions of the present disclosure can contain any amounts of these components suitable for the purpose of achieving the desired pharmacological properties and stability described herein. In addition, other pharmaceutically acceptable ingredients, such as adjuvants, antioxidants, buffers, colorants, compression aids, emulsifiers, emollients, encapsulating materials, fillers, flavoring agents, granulating agents, metal chelating agents, osmolality adjusting agents, pH adjusting agents, preservatives, solubilizers, adsorbents, stabilizers, sweeteners, surfactants, suspending agents, thickeners, or viscosity adjusting agents, can also be added to the pharmaceutical compositions.

[0090] In one embodiment, the pharmaceutical composition is a tablet pharmaceutical composition suitable for oral administration.

[0091] In a further embodiment, the tablet pharmaceutical composition comprises a. Compound 1; b. microcrystalline cellulose; c. lactose, d. hydroxypropyl cellulose; e. croscarmellose sodium, f. silicon dioxide; g. stearic acid or magnesium stearate, and optionally h. film coating.

[0092] In one embodiment, the tablet pharmaceutical composition comprises: a. Compound 1; B. Microcrystalline cellulose c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. stearic acid or magnesium stearate, and optionally h. film coating.

[0093] Tablet pharmaceutical compositions of Compound 1 can be expressed in terms of the weight percentage ("by weight") of each component present in the dosage form, where the sum of the weight percentages does not exceed 100%.

[0094] Thus, in one embodiment, the tablet pharmaceutical composition comprises: a. about 20% by weight to about 40% by weight of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 4 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0095] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20% by weight to about 40% by weight of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of anhydrous lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 4 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0096] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% by weight to about 35% by weight of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 6 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0097] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% by weight to about 35% by weight of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 4 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 1.5% by weight of magnesium stearate, and optionally, h. film coating.

[0098] Thus, in another embodiment, the tablet pharmaceutical composition comprises: a. about 20% by weight to about 40% by weight of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 2 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % silicon dioxide; g. about 1 to about 5% by weight of stearic acid, and optionally, h. film coating.

[0099] Thus, in another embodiment, the tablet pharmaceutical composition comprises: a. about 20% by weight to about 40% by weight of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of anhydrous lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 2 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 1 to about 5% by weight of stearic acid, and optionally, h. film coating.

[0100] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% by weight to about 35% by weight of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0101] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% by weight to about 35% by weight of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 1.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0102] In another embodiment, a tablet pharmaceutical composition comprises about 10 to about 150 mg of Compound 1 (free base equivalent) and pharmaceutically acceptable excipients selected from the group consisting of one or more diluents, one or more binders, one or more disintegrants, one or more disintegrants, one or more glidants, one or more lubricants, and optionally a film coating.

[0103] In another embodiment, a tablet pharmaceutical composition comprises about 10 to about 100 mg of Compound 1 and pharmaceutically acceptable excipients selected from the group consisting of one or more diluents, one or more binders, one or more disintegrants, one or more disintegrants, one or more glidants, one or more lubricants, and optionally a film coating.

[0104] In another embodiment, the tablet pharmaceutical composition comprises about 10 to about 90 mg of Compound 1, microcrystalline cellulose, lactose, hydroxypropyl cellulose, croscarmellose sodium, silicon dioxide, stearic acid or magnesium stearate, and optionally a film coating.

[0105] In another embodiment, the tablet pharmaceutical composition comprises about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, or 150 mg of Compound 1 (free base equivalent), microcrystalline cellulose, lactose, hydroxypropyl cellulose, croscarmellose sodium, silicon dioxide, stearic acid or magnesium stearate, and optionally a film coating.

[0106] In another embodiment, the tablet pharmaceutical composition comprises about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg of Compound 1 (free base equivalent), microcrystalline cellulose, lactose, hydroxypropyl cellulose, croscarmellose sodium, silicon dioxide, stearic acid or magnesium stearate, and optionally a film coating.

[0107] In one embodiment, the tablet pharmaceutical composition comprises: a. 15 to 150 mg of Compound 1 (free base equivalent); b. microcrystalline cellulose; c. lactose, d. hydroxypropyl cellulose; e. croscarmellose sodium, f. silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0108] In one embodiment, the tablet pharmaceutical composition comprises: a. 15 to 150 mg of Compound 1 (free base equivalent); b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0109] In one embodiment, the tablet pharmaceutical composition comprises: a. 15 to 100 mg of Compound 1; b. microcrystalline cellulose; c. lactose, d. hydroxypropyl cellulose; e. croscarmellose sodium, f. silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0110] In one embodiment, the tablet pharmaceutical composition comprises: a. 15 to 100 mg of Compound 1; b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0111] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20 mg of Compound 1; b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0112] In one embodiment, the tablet pharmaceutical composition comprises: a. about 40 mg of Compound 1; b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0113] In one embodiment, the tablet pharmaceutical composition comprises: a. about 60 mg of Compound 1; b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0114] In one embodiment, the tablet pharmaceutical composition comprises: a. about 80 mg of Compound 1; b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0115] In one embodiment, the tablet pharmaceutical composition comprises: a. about 100 mg of Compound 1; b. microcrystalline cellulose; c. anhydrous lactose; d. hydroxypropyl cellulose; e. croscarmellose sodium, f. colloidal silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. film coating.

[0116] In one embodiment, the tablet pharmaceutical composition comprises: i. about 120 mg of Compound 1; j. microcrystalline cellulose; k. anhydrous lactose; l. Hydroxypropyl cellulose; m. Croscarmellose sodium, n. Colloidal silicon dioxide, o. magnesium stearate or stearic acid, and optionally p. film coating.

[0117] In one embodiment, the tablet pharmaceutical composition comprises: a. about 18-23 mg of Compound 1; b. Approximately 30-35 mg of microcrystalline cellulose; c. approximately 15-18 mg of anhydrous lactose; d. approximately 1.5 to 4.5 mg of hydroxypropyl cellulose; e. Approximately 4 to 6 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. Approximately 0.5-0.7 mg of magnesium stearate, and optionally h. about 2 to 6 mg of film coating.

[0118] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20 mg of Compound 1; b. Approximately 30-35 mg of microcrystalline cellulose; c. approximately 15-18 mg of anhydrous lactose; d. approximately 1.5 to 4.5 mg of hydroxypropyl cellulose; e. Approximately 4 to 6 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. Approximately 0.5-0.7 mg of magnesium stearate, and optionally h. about 2 to 6 mg of film coating.

[0119] In one embodiment, the tablet pharmaceutical composition comprises: a. about 35-45 mg of Compound 1; b. Approximately 60-70 mg of microcrystalline cellulose; c. Approximately 30-40 mg of lactose; d. approximately 2 to 10 mg of hydroxypropyl cellulose; e. Approximately 8 to 12 mg of croscarmellose sodium; f. about 0.2 to 0.6 mg of silicon dioxide; g. Approximately 1 to 1.5 mg of magnesium stearate, and optionally, h. about 4 to 12 mg of film coating.

[0120] In one embodiment, the tablet pharmaceutical composition comprises: a. about 40 mg of Compound 1; b. Approximately 60-70 mg of microcrystalline cellulose; c. Approximately 30-40 mg of lactose; d. approximately 2 to 10 mg of hydroxypropyl cellulose; e. Approximately 8 to 12 mg of croscarmellose sodium; f. about 0.2 to 0.6 mg of silicon dioxide; g. Approximately 1 to 1.5 mg of magnesium stearate, and optionally, h. about 4 to 12 mg of film coating.

[0121] In one embodiment, the tablet pharmaceutical composition comprises: a. about 55-65 mg of Compound 1; b. Approximately 90-110 mg of microcrystalline cellulose; c. approximately 40-60 mg of anhydrous lactose; d. approximately 4 to 14 mg of hydroxypropyl cellulose; e. Approximately 12 to 20 mg of croscarmellose sodium; f. about 0.3 to 1 mg of colloidal silicon dioxide; g. Approximately 1.5 to 2.5 mg of magnesium stearate, and optionally h. about 6 to 18 mg of film coating.

[0122] In one embodiment, the tablet pharmaceutical composition comprises: a. about 60 mg of Compound 1; b. Approximately 90-110 mg of microcrystalline cellulose; c. approximately 40-60 mg of anhydrous lactose; d. approximately 4 to 14 mg of hydroxypropyl cellulose; e. Approximately 12 to 20 mg of croscarmellose sodium; f. about 0.3 to 1 mg of colloidal silicon dioxide; g. Approximately 1.5 to 2.5 mg of magnesium stearate, and optionally h. about 6 to 18 mg of film coating.

[0123] In one embodiment, the tablet pharmaceutical composition comprises: a. Approximately 70-90 mg of Compound 1; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 6 to 18 mg of hydroxypropyl cellulose; e. Approximately 15 to 25 mg of croscarmellose sodium; f. about 0.4 to 1.5 mg of colloidal silicon dioxide; g. Approximately 2-3 mg of magnesium stearate, and optionally h. about 8 to 26 mg of film coating.

[0124] In one embodiment, the tablet pharmaceutical composition comprises: a. about 80 mg of Compound 1; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 6 to 18 mg of hydroxypropyl cellulose; e. Approximately 15 to 25 mg of croscarmellose sodium; f. about 0.4 to 1.5 mg of colloidal silicon dioxide; g. Approximately 2-3 mg of magnesium stearate, and optionally h. about 8 to 26 mg of film coating.

[0125] In one embodiment, the tablet pharmaceutical composition comprises: a. about 18-23 mg of Compound 1; b. Approximately 30-40 mg of microcrystalline cellulose; c. approximately 15-20 mg of anhydrous lactose; d. approximately 3-7 mg of hydroxypropyl cellulose; e. approximately 3 to 7 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. about 2-4 mg of stearic acid, and optionally, h. about 2 to 5 mg of film coating.

[0126] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20 mg of Compound 1; b. Approximately 30-40 mg of microcrystalline cellulose; c. approximately 15-20 mg of anhydrous lactose; d. approximately 3-7 mg of hydroxypropyl cellulose; e. approximately 3 to 7 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. about 2-4 mg of stearic acid, and optionally, h. about 2 to 5 mg of film coating.

[0127] In one embodiment, the tablet pharmaceutical composition comprises: a. about 35-45 mg of Compound 1; b. Approximately 50-70 mg of microcrystalline cellulose; c. approximately 25-35 mg of anhydrous lactose; d. approximately 6 to 10 mg of hydroxypropyl cellulose; e. Approximately 6 to 10 mg of croscarmellose sodium; f. about 0.2 to 0.6 mg of colloidal silicon dioxide; g. approximately 4-8 mg of stearic acid, and optionally h. about 4 to 10 mg of film coating.

[0128] In one embodiment, the tablet pharmaceutical composition comprises: a. about 40 mg of Compound 1; b. Approximately 50-70 mg of microcrystalline cellulose; c. approximately 25-35 mg of anhydrous lactose; d. approximately 6 to 10 mg of hydroxypropyl cellulose; e. Approximately 6 to 10 mg of croscarmellose sodium; f. about 0.2 to 0.6 mg of colloidal silicon dioxide; g. approximately 4-8 mg of stearic acid, and optionally h. about 4 to 10 mg of film coating.

[0129] In one embodiment, the tablet pharmaceutical composition comprises: a. about 55-65 mg of Compound 1; b. Approximately 80-120 mg of microcrystalline cellulose; c. approximately 40-70 mg of anhydrous lactose; d. approximately 12-15 mg of hydroxypropyl cellulose; e. Approximately 12 to 15 mg of croscarmellose sodium; f. about 0.5-0.8 mg of colloidal silicon dioxide; g. approximately 6-12 mg of stearic acid, and optionally h. about 6 to 12 mg of film coating.

[0130] In one embodiment, the tablet pharmaceutical composition comprises: a. about 60 mg of Compound 1; b. Approximately 80-120 mg of microcrystalline cellulose; c. approximately 40-70 mg of anhydrous lactose; d. approximately 12-15 mg of hydroxypropyl cellulose; e. Approximately 12 to 15 mg of croscarmellose sodium; f. about 0.5-0.8 mg of colloidal silicon dioxide; g. approximately 6-12 mg of stearic acid, and optionally h. about 6 to 12 mg of film coating.

[0131] In one embodiment, the tablet pharmaceutical composition comprises: a. Approximately 70-90 mg of Compound 1; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 12-30 mg of hydroxypropyl cellulose; e. Approximately 12 to 30 mg of croscarmellose sodium; f. about 0.5 to 1.5 mg of colloidal silicon dioxide; g. approximately 8-16 mg of stearic acid, and optionally h. about 8 to 14 mg of film coating.

[0132] In one embodiment, the tablet pharmaceutical composition comprises: a. about 80 mg of Compound 1; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 12-30 mg of hydroxypropyl cellulose; e. Approximately 12 to 30 mg of croscarmellose sodium; f. about 0.5 to 1.5 mg of colloidal silicon dioxide; g. approximately 8-16 mg of stearic acid, and optionally h. about 8 to 14 mg of film coating.

[0133] In one embodiment, the tablet pharmaceutical composition comprises: a. about 100 mg of Compound 1; b. Approximately 140-160 mg of microcrystalline cellulose; c. approximately 70-90 mg of anhydrous lactose; d. approximately 15-25 mg of hydroxypropyl cellulose; e. Approximately 20-30 mg of croscarmellose sodium; f. about 0.8 to 2.0 mg of colloidal silicon dioxide; g. approximately 9-18 mg of stearic acid, and optionally h. about 10 to 30 mg of film coating.

[0134] In one embodiment, the tablet pharmaceutical composition comprises: a. about 120 mg of Compound 1; b. Approximately 165-195 mg of microcrystalline cellulose; c. approximately 80-100 mg of anhydrous lactose; d. Approximately 20-30 mg of hydroxypropyl cellulose; e. approximately 25-35 mg of croscarmellose sodium; f. about 1.0 to 2.5 mg of colloidal silicon dioxide; g. Approximately 10-20 mg of stearic acid, and optionally, h. about 15 to 35 mg of film coating. Crystalline solid form of the compound

[0135] As provided herein, Compound 1 can be present in the pharmaceutical compositions of the present disclosure as a crystalline (free base) solid form or as a crystalline salt.

[0136] Thus, in one embodiment, the tablet pharmaceutical composition comprises: a. about 20% to about 40% by weight of Compound 1 as a crystalline solid or a crystalline salt; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 4 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0137] In another embodiment, the tablet pharmaceutical composition comprises: a. about 20% to about 40% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 4 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0138] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20% to about 40% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of anhydrous lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 4 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0139] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 6 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0140] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 4 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 1.5% by weight of magnesium stearate, and optionally, h. film coating.

[0141] Thus, in another embodiment, the tablet pharmaceutical composition comprises: a. about 20% to about 40% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 2 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % silicon dioxide; g. about 1 to about 5% by weight of stearic acid, and optionally, h. film coating.

[0142] Thus, in another embodiment, the tablet pharmaceutical composition comprises: a. about 20% to about 40% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight of anhydrous lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 2 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 1 to about 5% by weight of stearic acid, and optionally, h. film coating.

[0143] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0144] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of Compound 1 as a crystalline solid or as a crystalline salt selected from the group consisting of an HCl salt of Compound 1, a fumarate salt of Compound 1, and a phosphate salt of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 1.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0145] In one embodiment, the pharmaceutical composition of the present disclosure comprises Compound 1 as a crystalline (free base) solid.

[0146] In one embodiment, the crystalline solid form of Compound 1 is characterized as Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O, Form P, or Form Q. In another embodiment, the crystalline solid form of Compound 1 is characterized as Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form K, Form O, or Form Q. In another embodiment, the crystalline solid form of Compound 1 is characterized as Form I, Form J, Form L, Form M, Form N, or Form P. Crystalline solid forms of Compound 1 characterized as Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O, Form P, or Form Q are disclosed in WO2020 / 123800, the entire contents of which are incorporated herein by reference for all purposes.

[0147] In one embodiment, the crystalline solid is characterized as Form A of Compound 1.

[0148] In one embodiment, the crystalline solid is characterized as Form B of Compound 1.

[0149] In one embodiment, the crystalline solid is characterized as Form C of Compound 1.

[0150] In one embodiment, the crystalline solid is characterized as Form D of Compound 1.

[0151] In one embodiment, the crystalline solid is characterized as Form E of Compound 1.

[0152] In one embodiment, the crystalline solid is characterized as Form F of Compound 1.

[0153] In one embodiment, the crystalline solid is characterized as Form G of Compound 1.

[0154] In one embodiment, the crystalline solid is characterized as Form H of Compound 1.

[0155] In one embodiment, the crystalline solid is characterized as Form I of Compound 1.

[0156] In one embodiment, the crystalline solid is characterized as Form J of Compound 1.

[0157] In one embodiment, the crystalline solid is characterized as Form K of Compound 1.

[0158] In one embodiment, the crystalline solid is characterized as Form L of Compound 1.

[0159] In one embodiment, the crystalline solid is characterized as Form M of Compound 1.

[0160] In one embodiment, the crystalline solid is characterized as Form N of Compound 1.

[0161] In one embodiment, the crystalline solid is characterized as Form O of Compound 1.

[0162] In one embodiment, the crystalline solid is characterized as Form P of Compound 1.

[0163] In one embodiment, the crystalline solid is characterized as Form Q of Compound 1.

[0164] Crystalline salt forms of Compound 1 In another embodiment, the pharmaceutical composition of the present disclosure comprises Compound 1 as a crystalline salt or a hydrate or solvate thereof.

[0165] In one embodiment, the crystalline salt is characterized as Compound 1 HCl Form A, Compound 1 HCl Form B, Compound 1 HCl Form C, or Compound 1 HCl Form D. Compound 1 HCl Form A, Compound 1 HCl Form B, Compound 1 HCl Form C, or Compound 1 HCl Form D are disclosed in WO2020 / 123800, which is incorporated by reference in its entirety for all purposes.

[0166] In one embodiment, the crystalline salt is characterized as Compound 1 HCl Form A.

[0167] In one embodiment, the crystalline salt is characterized as HCl Form B of Compound 1.

[0168] In one embodiment, the crystalline salt is characterized as Compound 1 HCl Form C.

[0169] In one embodiment, the crystalline salt is characterized as HCl Form D of Compound 1.

[0170] In one embodiment, the pharmaceutical composition disclosed herein comprises a crystalline fumarate salt of Compound 1, or a hydrate or solvate thereof. In some embodiments, the crystalline fumarate salt of Compound 1 is characterized as Compound 1 fumarate Form A or Compound 1 hemifumarate Form B. Crystalline fumarate salts of Compound 1 characterized as Compound 1 fumarate Form A or Compound 1 hemifumarate B are disclosed in WO2020 / 123800, the entire contents of which are incorporated herein by reference for all purposes.

[0171] In one embodiment, the crystalline salt is characterized as fumarate salt Form A of Compound 1.

[0172] In one embodiment, the crystalline salt is characterized as fumarate Form B of Compound 1.

[0173] In one embodiment, the pharmaceutical composition comprises a crystalline phosphate salt of Compound 1, or a hydrate or solvate thereof. In some embodiments, the crystalline phosphate salt of Compound 1 is characterized as phosphate Form A of Compound 1. A crystalline fumarate salt characterized as phosphate Form A of Compound 1 is disclosed in WO2020 / 123800, the entire contents of which are incorporated herein by reference for all purposes.

[0174] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of a hemifumarate salt of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 6 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0175] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of a hemifumarate salt of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 4 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 1.5% by weight of magnesium stearate, and optionally, h. film coating.

[0176] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of hemifumarate Form B of Compound 1; b. about 37% to about 43% by weight of microcrystalline cellulose; c. about 18 to about 22% by weight of anhydrous lactose; d. about 2 to about 6 weight percent hydroxypropyl cellulose; e. about 5 to about 7% by weight of croscarmellose sodium; f. about 0.2 to about 0.4 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. film coating.

[0177] In one embodiment, the tablet pharmaceutical composition comprises: a. about 27.75% by weight of the hemifumarate salt of Compound 1; b. about 41.47% by weight of microcrystalline cellulose; c. about 20.73% by weight of anhydrous lactose; d. about 3% by weight of hydroxypropyl cellulose; e. about 6% by weight of croscarmellose sodium; f. about 0.3 wt. % colloidal silicon dioxide; g. about 0.75% by weight of magnesium stearate, and optionally, h. film coating.

[0178] In one embodiment, the tablet pharmaceutical composition comprises: a. about 27.75% by weight of Compound 1 hemifumarate Form B; b. about 41.47% by weight of microcrystalline cellulose; c. about 20.73% by weight of anhydrous lactose; d. about 3% by weight of hydroxypropyl cellulose; e. about 6% by weight of croscarmellose sodium; f. about 0.3 wt. % colloidal silicon dioxide; g. about 0.75% by weight of magnesium stearate, and optionally, h. film coating.

[0179] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20-25 mg of the hemifumarate salt of Compound 1; b. Approximately 30-35 mg of microcrystalline cellulose; c. approximately 15-18 mg of anhydrous lactose; d. approximately 1.5 to 4.5 mg of hydroxypropyl cellulose; e. Approximately 4 to 6 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. Approximately 0.5-0.7 mg of magnesium stearate, and optionally h. about 2 to 6 mg of film coating.

[0180] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20-25 mg of hemifumarate Form B of Compound 1; b. Approximately 30-35 mg of microcrystalline cellulose; c. approximately 15-18 mg of anhydrous lactose; d. approximately 1.5 to 4.5 mg of hydroxypropyl cellulose; e. Approximately 4 to 6 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. Approximately 0.5-0.7 mg of magnesium stearate, and optionally h. about 2 to 6 mg of film coating.

[0181] In one embodiment, the tablet pharmaceutical composition comprises: a. about 22.20 mg of Compound 1 hemifumarate Form B; b. Approximately 30-35 mg of microcrystalline cellulose; c. approximately 15-18 mg of anhydrous lactose; d. approximately 1.5 to 4.5 mg of hydroxypropyl cellulose; e. Approximately 4 to 6 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. Approximately 0.5-0.7 mg of magnesium stearate, and optionally h. about 2 to 6 mg of film coating.

[0182] In one embodiment, the tablet pharmaceutical composition comprises: a. about 22.20 mg of Compound 1 hemifumarate Form B; b. Approximately 33.17 mg of microcrystalline cellulose; c. approximately 16.59 mg of anhydrous lactose; d. about 2.4 mg of hydroxypropyl cellulose; e. approximately 4.8 mg of croscarmellose sodium; f. about 0.24 mg of colloidal silicon dioxide; g. about 0.6 mg magnesium stearate, and optionally h. about 3.2 mg of a film coating.

[0183] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of a hemifumarate salt of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0184] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of a hemifumarate salt of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 1.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0185] In one embodiment, the tablet pharmaceutical composition comprises: a. about 25% to about 35% by weight of hemifumarate Form B of Compound 1; b. about 35% to about 40% by weight of microcrystalline cellulose; c. about 16 to about 22% by weight of anhydrous lactose; d. about 3 to about 7 weight percent hydroxypropyl cellulose; e. about 3 to about 7% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 0.5 to about 3.5% by weight of stearic acid, and optionally, h. film coating.

[0186] In one embodiment, the tablet pharmaceutical composition comprises: a. about 27.75% by weight of the hemifumarate salt of Compound 1; b. about 38.63% by weight of microcrystalline cellulose; c. about 19.32% by weight of anhydrous lactose; d. about 5% by weight of hydroxypropyl cellulose; e. about 6% by weight of croscarmellose sodium; f. about 0.3 wt. % colloidal silicon dioxide; g. about 3% by weight of magnesium stearate, and optionally, h. film coating.

[0187] In one embodiment, the tablet pharmaceutical composition comprises: a. about 27.75% by weight of Compound 1 hemifumarate Form B; b. about 38.63% by weight of microcrystalline cellulose; c. about 19.32% by weight of anhydrous lactose; d. about 5% by weight of hydroxypropyl cellulose; e. about 6% by weight of croscarmellose sodium; f. about 0.3 wt. % colloidal silicon dioxide; g. about 3% by weight of magnesium stearate, and optionally, h. film coating.

[0188] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20-25 mg of the hemifumarate salt of Compound 1; b. Approximately 30-40 mg of microcrystalline cellulose; c. approximately 15-20 mg of anhydrous lactose; d. approximately 3-7 mg of hydroxypropyl cellulose; e. approximately 3 to 7 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. about 2-4 mg of stearic acid, and optionally, h. about 2 to 5 mg of film coating.

[0189] In one embodiment, the tablet pharmaceutical composition comprises: a. about 20-25 mg of hemifumarate Form B of Compound 1; b. Approximately 30-40 mg of microcrystalline cellulose; c. approximately 15-20 mg of anhydrous lactose; d. approximately 3-7 mg of hydroxypropyl cellulose; e. approximately 3 to 7 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. about 2-4 mg of stearic acid, and optionally, h. about 2 to 5 mg of film coating.

[0190] In one embodiment, the tablet pharmaceutical composition comprises: a. about 22.20 mg of Compound 1 hemifumarate Form B; b. Approximately 30-40 mg of microcrystalline cellulose; c. approximately 15-20 mg of anhydrous lactose; d. approximately 3-7 mg of hydroxypropyl cellulose; e. approximately 3 to 7 mg of croscarmellose sodium; f. about 0.1 to 0.3 mg of colloidal silicon dioxide; g. about 2-4 mg of stearic acid, and optionally, h. about 2 to 5 mg of film coating.

[0191] In one embodiment, the tablet pharmaceutical composition comprises: a. about 22.20 mg of Compound 1 hemifumarate Form B; b. Approximately 30.9 mg of microcrystalline cellulose; c. approximately 15.46 mg of anhydrous lactose; d. Approximately 4 mg of hydroxypropyl cellulose; e. approximately 4.8 mg of croscarmellose sodium; f. about 0.24 mg of colloidal silicon dioxide; g. about 2.4 mg stearic acid, and optionally, h. about 3.2 mg of a film coating.

[0192] In one embodiment, the tablet pharmaceutical composition comprises: a. about 83-93 mg of the hemifumarate salt of Compound 1; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 12-30 mg of hydroxypropyl cellulose; e. Approximately 12 to 30 mg of croscarmellose sodium; f. about 0.5 to 1.5 mg of colloidal silicon dioxide; g. approximately 8-16 mg of stearic acid, and optionally h. about 8 to 14 mg of film coating.

[0193] In one embodiment, the tablet pharmaceutical composition comprises: a. about 83-93 mg of hemifumarate Form B of Compound 1; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 12-30 mg of hydroxypropyl cellulose; e. Approximately 12 to 30 mg of croscarmellose sodium; f. about 0.5 to 1.5 mg of colloidal silicon dioxide; g. approximately 8-16 mg of stearic acid, and optionally h. about 8 to 14 mg of film coating.

[0194] In one embodiment, the tablet pharmaceutical composition comprises: a. about 88.78 mg of Compound 1 hemifumarate Form B; b. Approximately 120-150 mg of microcrystalline cellulose; c. approximately 60-80 mg of anhydrous lactose; d. approximately 12-30 mg of hydroxypropyl cellulose; e. Approximately 12 to 30 mg of croscarmellose sodium; f. about 0.5 to 1.5 mg of colloidal silicon dioxide; g. approximately 8-16 mg of stearic acid, and optionally h. about 8 to 14 mg of film coating.

[0195] In one embodiment, the tablet pharmaceutical composition comprises: a. about 88.78 mg of Compound 1 hemifumarate Form B; b. Approximately 123.62 mg of microcrystalline cellulose; c. approximately 61.82 mg of anhydrous lactose; d. Approximately 16 mg of hydroxypropyl cellulose; e. approximately 19.2 mg of croscarmellose sodium; f. about 0.96 mg of colloidal silicon dioxide; g. about 9.6 mg stearic acid, and optionally, h. about 12.8 mg of film coating.

[0196] In one embodiment, the tablet pharmaceutical composition comprises: a. about 100-120 mg of hemifumarate Form B of Compound 1; b. Approximately 140-160 mg of microcrystalline cellulose; c. approximately 70-90 mg of anhydrous lactose; d. approximately 15-25 mg of hydroxypropyl cellulose; e. Approximately 20-30 mg of croscarmellose sodium; f. about 0.8 to 2.0 mg of colloidal silicon dioxide; g. approximately 9-18 mg of stearic acid, and optionally h. about 10 to 30 mg of film coating.

[0197] In one embodiment, the tablet pharmaceutical composition comprises: a. about 111 mg of Compound 1 hemifumarate Form B; b. Approximately 140-160 mg of microcrystalline cellulose; c. approximately 70-90 mg of anhydrous lactose; d. approximately 15-25 mg of hydroxypropyl cellulose; e. Approximately 20-30 mg of croscarmellose sodium; f. about 0.8 to 2.0 mg of colloidal silicon dioxide; g. approximately 9-18 mg of stearic acid, and optionally h. about 10 to 30 mg of film coating.

[0198] In one embodiment, the tablet pharmaceutical composition comprises: a. about 111 mg of Compound 1 hemifumarate Form B; b. Approximately 154.52 mg of microcrystalline cellulose; c. approximately 77.28 mg of anhydrous lactose; d. Approximately 20 mg of hydroxypropyl cellulose; e. approximately 24 mg of croscarmellose sodium; f. about 1.2 mg of colloidal silicon dioxide; g. about 12 mg stearic acid, and optionally, h. about 16 mg of film coating.

[0199] In one embodiment, the tablet pharmaceutical composition comprises: a. about 130-140 mg of hemifumarate Form B of Compound 1; b. Approximately 165-195 mg of microcrystalline cellulose; c. approximately 80-100 mg of anhydrous lactose; d. Approximately 20-30 mg of hydroxypropyl cellulose; e. approximately 25-35 mg of croscarmellose sodium; f. about 1.0 to 2.5 mg of colloidal silicon dioxide; g. Approximately 10-20 mg of stearic acid, and optionally, h. about 15 to 35 mg of film coating.

[0200] In one embodiment, the tablet pharmaceutical composition comprises: a. about 132 mg of Compound 1 hemifumarate Form B; b. Approximately 165-195 mg of microcrystalline cellulose; c. approximately 80-100 mg of anhydrous lactose; d. Approximately 20-30 mg of hydroxypropyl cellulose; e. approximately 25-35 mg of croscarmellose sodium; f. about 1.0 to 2.5 mg of colloidal silicon dioxide; g. Approximately 10-20 mg of stearic acid, and optionally, h. about 15 to 35 mg of film coating.

[0201] In one embodiment, the tablet pharmaceutical composition comprises: a. about 132 mg of Compound 1 hemifumarate Form B; b. Approximately 185.42 mg of microcrystalline cellulose; c. approximately 92.74 mg of anhydrous lactose; d. Approximately 24 mg of hydroxypropyl cellulose; e. approximately 28.8 mg of croscarmellose sodium; f. about 1.44 mg of colloidal silicon dioxide; g. about 14.4 mg stearic acid, and optionally, h. about 19.2 mg of a film coating.

[0202] Treatment method In yet another aspect, the present invention relates to a method for treating a disease, disorder, or syndrome mediated at least in part by modulating the in vivo activity of a protein kinase, comprising administering to a subject in need of treatment for the disease, disorder, or syndrome a crystalline form or crystalline salt form of Compound 1, as described herein.

[0203] In one embodiment of this aspect, the disease, disorder, or syndrome mediated at least in part by modulating the in vivo activity of a protein kinase is cancer.

[0204] In one embodiment, the cancer is selected from cardiac cancer, head and neck cancer, lung cancer, colon cancer, gastrointestinal cancer, breast cancer, genitourinary cancer, liver cancer, bone cancer, thyroid cancer, cancer of the nervous system, gynecological cancer, blood cancer, skin cancer, and adrenal gland cancer.

[0205] In further embodiments, the cardiac cancer is selected from angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and teratoma.

[0206] In another further embodiment, the head and neck cancer is selected from squamous cell carcinoma of the head and neck, laryngeal and hypopharyngeal cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, salivary gland cancer, oral cavity and oropharyngeal cancer.

[0207] In another further embodiment, the lung cancer is selected from squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma, and non-small cell lung carcinoma; alveolar (bronchial) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroitin hamartoma, and mesothelioma.

[0208] In another further embodiment, the colon cancer is selected from colorectal carcinoma, adenocarcinoma, gastrointestinal stromal tumor, lymphoma, carcinoid, and Turcot's syndrome.

[0209] In another further embodiment, the gastrointestinal cancer is selected from gastric carcinoma, gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, esophageal adenocarcinoma, esophageal leiomyosarcoma, esophageal lymphoma, gastric carcinoma, gastric lymphoma, gastric leiomyosarcoma, pancreatic ductal adenocarcinoma, pancreatic insulinoma, pancreatic glucagonoma, pancreatic gastrinoma, pancreatic carcinoid tumor, vipoma, small intestinal adenocarcinoma, small intestinal lymphoma, small intestinal carcinoid tumor, small intestinal Kaposi's sarcoma, small intestinal leiomyoma, small intestinal hemangioma, small intestinal lipoma, small intestinal neurofibroma, small intestinal fibroma, large intestinal adenocarcinoma, large intestinal tubular adenoma, large intestinal villous adenoma, large intestinal hamartoma, and large intestinal leiomyoma.

[0210] In another further embodiment, the breast cancer is selected from metastatic breast cancer, ductal carcinoma in situ, invasive ductal carcinoma, tubular carcinoma, medullary carcinoma, mucinous carcinoma, lobular carcinoma in situ, and triple-negative breast cancer;

[0211] In another further embodiment, the genitourinary tract cancer is selected from renal adenocarcinoma, renal nephroblastoma, renal lymphoma, renal cell carcinoma, squamous cell carcinoma of the bladder or urethra, transitional cell carcinoma of the bladder or urethra, adenocarcinoma of the bladder or urethra, urothelial carcinoma of the bladder or urethra, prostate adenocarcinoma, prostate sarcoma, castration-resistant prostate cancer, seminoma, testicular teratoma, embryonal carcinoma, testicular teratocarcinoma, testicular choriocarcinoma, testicular sarcoma, testicular interstitial cell carcinoma, testicular fibroma, testicular fibroadenoma, testicular adenomatous tumor, testicular lipoma, clear cell carcinoma, and papillary carcinoma.

[0212] In another further embodiment, the liver cancer is selected from hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

[0213] In another further embodiment, the bone cancer is selected from osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, reticulum cell sarcoma, multiple myeloma, malignant giant cell tumor chordoma, osteochondroma, benign cartilage tumor, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor.

[0214] In another further embodiment, the thyroid cancer is selected from medullary thyroid carcinoma, differentiated thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma, Hurthle cell carcinoma, and anaplastic thyroid carcinoma.

[0215] In another further embodiment, the nervous system cancer is selected from osteoma of the skull, hemangioma of the skull, granuloma of the skull, xanthomas of the skull, osteitis deformans of the skull, meningioma of the meninges, meningeal sarcoma, gliomatosis, astrocytoma of the brain, medulloblastoma, glioma, ependymoma of the brain, germinoma [pinealoma], glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, spinal neurofibroma, meningioma, and sarcoma of the brain.

[0216] In another further embodiment, the gynecological cancer is selected from endometrial cancer, cervical cancer, preneoplastic cervical dysplasia; ovarian cancer selected from serous cystadenocarcinoma, mucinous cystadenocarcinoma, and unclassified ovarian cancer, granulosa-theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, and malignant teratoma; vulvar squamous cell carcinoma, vulvar carcinoma in situ, vulvar adenocarcinoma, vulvar fibrosarcoma, vulvar melanoma, vaginal clear cell carcinoma, vaginal squamous cell carcinoma, embryonal rhabdomyosarcoma, and fallopian tube carcinoma.

[0217] In another further embodiment, the hematological cancer is selected from myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndromes, Hodgkin's disease, and non-Hodgkin's lymphoma [malignant lymphoma].

[0218] In another further embodiment, the skin cancer is selected from malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, lenticular dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, and psoriasis.

[0219] In another further embodiment, the adrenal cancer is neuroblastoma.

[0220] In another further embodiment, the cancer is advanced clear cell renal cell carcinoma, hormone receptor positive breast cancer, or castration-resistant prostate cancer.

[0221] In another further embodiment, the cancer is advanced clear cell renal cell carcinoma.

[0222] In another further embodiment, the cancer is hormone receptor positive breast cancer.

[0223] In another further embodiment, the cancer is castration-resistant prostate cancer.

[0224] In another embodiment, the cancer is non-clear cell renal cell carcinoma.

[0225] In another embodiment, the cancer is clear cell renal cell carcinoma.

[0226] Labeled Compounds and Assay Methods Another aspect of the present invention relates to labeled crystalline forms or crystalline salt forms (radiolabeled, fluorescently labeled, etc.) of the present invention that are useful not only in imaging methods but also in in vitro and in vivo assays for localizing and quantifying TAM kinase in tissue samples, including humans, and for identifying TAM kinase ligands by binding inhibitory labeled compounds. Accordingly, the present invention includes TAM kinase assays comprising such labeled compounds.

[0227] The present invention further includes isotopically labeled crystalline forms or crystalline salt forms of the present invention. An "isotopically labeled" or "radiolabeled" compound is a crystalline form or crystalline salt form of the present invention in which one or more atoms have been replaced, i.e., substituted, with an atom having an atomic mass or mass number different from that normally found in nature (i.e., naturally occurring). Suitable radionuclides that can be incorporated into the crystalline forms or crystalline salt forms of the present invention include, but are not limited to: 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br,123 I, 124 I, 125 I and 131 The radionuclide incorporated into the present radiolabeled compounds will depend on the particular application of the radiolabeled compound. For example, in in vitro metalloprotease labeling and competition assays, 3 H, 14 C. 82 Br, 125 I, 131 I, or 35 Compounds incorporating S are generally most useful. For radioimaging applications, 11 C. 18 F, 125 I, 123 I, 124 I, 131 I, 75 Br, 76 Br or 77 Br is generally most useful. In some embodiments, the crystalline forms or crystalline salt forms described herein have one or more hydrogens, such as hydrogens attached to carbon atoms, replaced with deuterium. Such compounds have increased resistance to metabolism and are therefore useful for extending the half-life of any compound when administered to mammals, particularly humans.

[0228] It is understood that a "radiolabeled" or "labeled compound" is a compound that incorporates at least one radionuclide. In some embodiments, the radionuclide is 3 H, 14 C. 125 I, 35 S, and 82 Br.

[0229] The present invention can further include synthetic methods for incorporating radioisotopes into the crystalline forms or crystalline salt forms of the present invention. Synthetic methods for incorporating radioisotopes into organic compounds are well known in the art, and one of ordinary skill in the art will readily recognize methods applicable to the compounds of the present invention.

[0230] The labeled compounds of the present invention can be used in screening assays to identify / evaluate compounds. For example, a labeled newly synthesized or identified compound (i.e., a test compound) can be evaluated for its ability to bind to TAM by tracking the label and monitoring its concentration fluctuations when contacting TAM kinase. For example, a (labeled) test compound can be evaluated for its ability to reduce the binding of another compound (i.e., a standard compound) known to bind to TAM kinase. Thus, the ability of a test compound to compete with a standard compound for binding to TAM kinase is directly correlated with its binding affinity. Conversely, in some other screening assays, the standard compound is labeled, and the test compound is not labeled. Therefore, to evaluate the competition between a standard compound and a test compound, the concentration of the labeled standard compound can be monitored to determine the relative binding affinity of the test compound.

[0231] Example General Experimental Methods

[0232] Aqueous Slurry Experiments: Compound 1 salts with aqueous solubility less than 1 mg / mL were slurried in 20 mL of water at ambient temperature for 1 day, and the solids were then collected by vacuum filtration and analyzed by XRPD.

[0233] Crash Cooling (CC): Concentrated solutions of compound 1 and different counterions were prepared in MeOH with stirring at elevated temperatures. The capped vial containing the hot solution was transferred to a freezer (approximately -20°C) and rapidly cooled. The solid that formed was collected. If no solid was observed, further crystallization methods were used.

[0234] Crash Precipitation (CP): Clear solutions of compound 1 and coformer were prepared in different solvents at room temperature. Aliquots of various antisolvents were slowly added to the solutions with gentle stirring until the solids crashed out of solution. Each mixture was stirred for a specific period of time. The solids formed were collected by positive pressure filtration.

[0235] Fast Cool (FC): Concentrated solutions of compound 1 and different counterions were prepared in acetone or MeOH at elevated temperatures with stirring. The capped vial containing the hot solution was transferred to a benchtop at ambient temperature. The solid that formed was collected. If no solid was observed, further crystallization methods were used.

[0236] Fast evaporation (FE): Clear solutions of compound 1 and coformer were prepared in different solvents. The vials were left uncapped and the solvent was allowed to evaporate at ambient conditions.

[0237] Interconversion Slurry: A slurry of Form A of Compound 1 was prepared by adding enough solid to a given solvent system at ambient conditions so that some residual solid remained dissolved. The mixture was then stirred for an extended period of time to achieve saturation. The desired form of solid was then added to an aliquot of the saturated solution (filtered through a 0.2 μm nylon filter) so that some residual solid remained dissolved. The mixture was then stirred for an extended period of time at ambient temperature, and the solid was isolated.

[0238] Isolation Methods: In general, non-ambient temperature samples were isolated immediately after removal from their respective temperature controllers to minimize equilibration to ambient temperature before isolating the solids.

[0239] Decanting the liquid phase: A portion of the solids isolated by solution-based crystallization methods was recovered by centrifuging the suspension (if necessary) and discarding the liquid phase, leaving behind the moist solid. Unless otherwise specified herein as "moisture analyzed," the solids were roughly dried (e.g., air-dried or dried under nitrogen).

[0240] Positive pressure filtration: Solids were collected on 0.2 μm nylon or PTFE filters by forcing the slurry through a syringe and Swinnex filter holder assembly. Generally, solids were roughly dried by blowing air through the filter with a 20 mL syringe. Where "analyzed wet" is designated herein, the solids were left wet with the mother liquor. Some samples were further roughly dried with a gentle stream of nitrogen gas before analysis.

[0241] Vacuum filtration: Solids were collected by vacuum filtration onto a paper or nylon filter and roughly air-dried on the filter under reduced pressure before being transferred to a vial.

[0242] Reaction crystallization (RC): Compound 1 and a mixture of different coformers were combined in a hot acetone slurry such that the molar concentration of the coformer was 2 times higher than that of the API. The solution was stirred for a predetermined time. When a clear solution was observed, further crystallization methods were used.

[0243] Stability testing: Different salts of Compound 1 were placed in open vials in a stability testing chamber (e.g., saturated sodium chloride solution at 60% or 75% relative humidity (RH)). The RH chamber was placed in an oven (e.g., at 25°C or 40°C) for a set period of time. Each sample was analyzed by PLM and XRPD at the end of this period.

[0244] Dissolution test: The dissolution release of Compound 1 in different pharmaceutical compositions of Compound 1 was investigated by high performance liquid chromatography (HPLC). The pharmaceutical compositions or tablets of Compound 1 were diluted to 37.0±0.5 ℃ The solution was added to a dissolution medium of 0.375% Triton® X-100 in 0.01 N HCl at a temperature of 5°C. Sample solutions were withdrawn for HPLC analysis at 5, 10, 20, 30, 45, 60, 90, 120, 10, 180, and 210 minutes.

[0245] Slow Cooling (SC): Concentrated solutions of compound 1 and different coformers were prepared in various solvents at elevated temperatures with stirring. Each vial was capped in a heated sample block, the hot plate was turned off, and each vial was slowly cooled to ambient temperature in a heated vial block. Once the clear solutions had cooled to ambient temperature, they were further cooled in a refrigerator (5-7 °C) and / or freezer (approximately -20 °C). If no solids were observed, further crystallization methods were used.

[0246] Slow evaporation: Solutions were prepared in different solvents with stirring and typically filtered through 0.2 μm nylon or PTFE filters. Unless otherwise noted, each solution was evaporated at ambient conditions from a covered vial (e.g., loosely capped or covered with perforated aluminum foil). Each solution was evaporated to dryness unless specified as partial evaporation (a small amount of solvent remaining in the solid), in which case each solid was isolated as described herein.

[0247] Solubility estimation: Aliquots of different solvents were added to a measured amount of Compound 1 and stirred (usually with sonication) at the temperature stated until complete dissolution was achieved as judged visually. If dissolution occurred after the addition of the first aliquot, the value is recorded as ">". If dissolution did not occur, the value is recorded as '<'.

[0248] Estimation of aqueous solubility: Aliquots of water were added to measured amounts of different salts of Compound 1 and sonicated.

[0249] Slurry experiments: Saturated solutions of Compound 1 and different coformers were prepared in various solvents and solvent mixtures. Each mixture was stirred at ambient and elevated temperatures for the indicated times. Solids were recovered by the methods described and further crystallization methods were used as needed.

[0250] Vacuum Oven Desolvation: Desolvation was attempted on salts of Compound 1 that were determined to be solvates by different analytical methods. Samples were placed in a vacuum oven at temperatures ranging from ambient to 80°C for a specified period of time. Each sample was analyzed by XRPD and / or TGA to determine whether desolvation was successful.

[0251] Vapor diffusion: Concentrated solutions were prepared in different solvents and filtered, typically through 0.2 μm nylon or PTFE filters. The filtered solutions were dispensed into small vials, which were then placed into a larger vial containing the antisolvent. The smaller vial was left uncapped, while the larger vial was capped and allowed to vapor diffuse. Any solids present were isolated as described herein.

[0252] Steam stress: The selected solid was transferred to a small vial and placed in a larger vial containing solvent. The small vial was left uncapped, while the larger vial was capped to create steam stress.

[0253] Coformer means one or more pharmaceutically acceptable bases and / or pharmaceutically acceptable acids disclosed herein in connection with Compound 1. Examples of coformers used herein include fumaric acid, HCl, and phosphoric acid.

[0254] Equipment Method

[0255] Differential Scanning Calorimetry (DSC): Differential scanning calorimetry (DSC) was performed using a Mettler-Toledo DSC3+ differential scanning calorimeter. Temperature calibration was performed using adamantane, phenyl salicylate, indium, tin, and zinc. Samples were placed in hermetically sealed or open aluminum DSC pans, and their weights were accurately recorded. A weighed aluminum pan, configured as the sample pan, was placed on the reference side of the cell. Samples were analyzed at a heating rate of 10°C / min from -30 to 250°C. Thermograms are plotted by reference temperature (x-axis), but results are recorded according to the sample temperature.

[0256] Dynamic Vapor Sorption (DVS)

[0257] a. VTI: Automated vapor sorption (VS) data were collected on a VTI SGA-100 vapor sorption analyzer. NaCl and PVP were used as calibration standards. Samples were dried prior to analysis. Sorption and desorption data were collected under a nitrogen purge over the range of 5% to 95% RH in 10% RH increments. The equilibration criteria used for analysis were a weight change of less than 0.0100 wt% in 5 minutes with a maximum equilibration time of 3 hours. Data were not collected on the initial moisture content of the samples.

[0258] b. Intrinsic: Automated vapor sorption (VS) data were collected on a Surface Measurement System DVS Intrinsic instrument. Samples were not dried prior to analysis. Sorption and desorption data were collected under a nitrogen purge over the range of 5% to 95% RH in 10% RH increments. The equilibrium criteria used for analysis were a weight change of less than 0.0100 wt% in 5 minutes with a maximum equilibration time of 3 hours. Data were not collected on the initial moisture content of the samples.

[0259] Hot Stage Microscopy (HSM): Hot stage microscopy was performed using a Linkam hot stage (FTIR600) mounted on a Leica DM LP microscope equipped with a SPOT Insight™ color digital camera. Temperature calibration was performed using USP melting point standards. Samples were placed on a coverslip, and a second coverslip was placed on top of the sample. While the stage was heated, each sample was visually observed using a 20x objective with crossed polarizers and a primary red compensator. Images were captured using SPOT software (v. 4.5.9).

[0260] Optical microscopy: Each sample was observed under a Motic or Wolfe optical microscope equipped with crossed polarizers or a Leica stereomicroscope equipped with a primary red compensator with crossed polarizers.

[0261] pKa and logP measurements: pKa and logP measurements were performed by Pion Inc. / Sirius Analytical Instruments Ltd. (East Sussex, United Kingdom).

[0262] Solution proton nuclear magnetic resonance spectroscopy ( 1 HNMR):Solution 1 H NMR spectra were obtained by Spectral Data Services (Champaign, IL). Each sample was prepared by dissolving approximately 5–10 mg of sample in DMSO-d6. Data acquisition parameters are listed on the first page of each spectrum in the data section of this report.

[0263] Thermogravimetric Analysis (TGA): Thermogravimetric analysis was performed using a Mettler Toledo TGA / DSC3+ analyzer. Temperature calibration was performed using phenyl salicylate, indium, tin, and zinc. Samples were placed in aluminum pans. The open pans were inserted into a TG furnace. The furnace was heated under nitrogen. Each sample was heated from ambient to 350°C at a heating rate of 2, 5, or 10°C / min. Thermograms are plotted by reference temperature (x-axis), but results are recorded according to the sample temperature.

[0264] X-ray powder analysis (XRPD)

[0265] a. Reflection: XRPD patterns were collected on a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu Kα radiation generated using a long fine focus source and nickel filter at room temperature (298 Kelvin). The diffractometer was configured using a symmetric Bragg-Brentano geometry. Prior to analysis, a silicon specimen (NIST SRM 640e) was analyzed to confirm that the observed position of the Si 111 peak matched the NIST-certified position. Sample specimens were loaded into wells. Anti-scatter slits (SS) were used to minimize background caused by air. Soller slits were used for the incident and diffracted beams to minimize spread from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) positioned 240 mm from the sample and Data Collector software v.2.2b. Data acquisition parameters for each pattern, including the divergence slit (DS) and incident beam SS, are displayed above the images in the data section of this report.

[0266] b. Transmission: XRPD patterns were collected on a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu radiation generated using an Optix long fine focus source at room temperature (298 Kelvin). An elliptically graded multilayer mirror was used to focus the Cu Kα X-rays through the specimen onto the detector. Prior to analysis, a silicon specimen (NIST SRM 640e) was analyzed to confirm that the observed position of the Si 111 peak matched the NIST-certified position. Sample specimens were sandwiched between 3 μm thick films and analyzed in transmission geometry. A beam stop, short anti-scatter extension, and an anti-scatter knife edge were used to minimize background caused by air. Soller slits were used on the incident and diffracted beams to minimize divergence from the axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) positioned 240 mm from the specimen and Data Collector software v.2.2b. The data acquisition parameters for each pattern are displayed above the images in the data section of this report, including the divergence slit (DS) in front of the mirror.

[0267] XRPD Indexing

[0268] Indexing and structure refinement are computational tests. In the referenced figures for a particular indexed XRPD pattern, agreement between the observed peaks and the accepted peak positions marked with bars indicates a consistent unit cell determination. Successful pattern indexing indicates that the sample is composed primarily of a single crystalline phase, unless otherwise noted. The assigned extinction symbols, unit cell parameters, and space groups consistent with the derived quantities are tabulated.

[0269] Compound Preparation Example Preparation Example 1: Synthesis of Compound 1

[0270] Step 1: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide (4): [ka]

[0271] To a solution of compound 2 (10 g, 44.80 mmol, 1 equiv.) and compound 3 (5.87 g, 53.8 mmol, 1.2 equiv.) in dimethylacetamide (DMA) (60 mL) was added 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine hydrochloride (EDCI) (10.31 g, 53.8 mmol, 1.2 equiv.). The mixture was vigorously stirred at 20 °C until the reaction was complete. The mixture was poured into saturated aqueous NaHCO (aq.) (400 mL) and extracted with EtOAc (4 × 100 mL). The combined organic phase was washed with saturated aqueous NaCl (100 mL), dried over anhydrous NaSO, and concentrated to give compound 4 (21 g, crude) (50% purity). 1 C 17 H 15 MS (EI) of FN2O3, actual value 314.9 (MH+).

[0272] Step 2: Methyl 4-[4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropane-carbonyl]amino]phenoxy]-7-methoxyquinoline-6-carboxylate (6): [ka]

[0273] A mixture of compound 4 (5.99 g, 9.5 mmol, 1.2 equiv.), compound 5 (2 g, 8.0 mmol, 1.0 equiv.), Pd(OAc) (89 mg, 397.4 μmol, 0.05 equiv.), rac-2-(di-tert-butylphosphino)-1,1'-binaphthyl (TrixiePhos, 316.71 mg, 794.7 μmol, 0.1 equiv.), and KPO (2.53 g, 11.9 mmol, 1.5 equiv.) in anisole (50 mL) was stirred at 110 °C for 2 hours (h) under a nitrogen atmosphere. The mixture was filtered, and the filtrate was concentrated. The residue was purified by flash silica gel chromatography (petroleum ether: EtOAc = 1:1 to EtOAc: MeOH = 20:1). Compound 6 was obtained (2.6 g, 61.8% yield). 1 HNMR(400MHz,CDCl3)δ9.38(s,1H),8.80(s,1H),8.63(d,2H),7.64(d,2H),7.54-7.41(m,3H),7.18(d, 2H),7.09-7.01(m,2H),6.43(d,1H),4.05(s,3H),3.97(s,3H),1.78-1.72(m,2H),1.69-1.63(m,2H);C 29 H 24 MS(EI) measured value of FN3O6 is 530.0 (MH+).

[0274] Step 3: 4-[4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropane-carbonyl]amino]phenoxy]-7-methoxyquinoline-6-carboxylic acid (7): [ka]

[0275] To a solution of compound 6 (1.8 g, 3.4 mmol, 1 equiv.) in tetrahydrofuran (THF) (15 mL) and MeOH (15 mL) was added 2 M aqueous NaOH (7 mL, 4.1 equiv.). The mixture was stirred at 6–13 °C for 4 h. The mixture was adjusted to pH = ∼8 with 1 M aqueous HCl and concentrated to remove the solvent. Water (50 mL) was added, and the mixture was adjusted to pH = ∼6 with 1 M aqueous HCl. The resulting precipitate was filtered, washed with water (2 × 10 mL), and dried under vacuum. Compound 7 was obtained (1.7 g, 97.0% yield). 1 HNMR(400MHz,DMSO-d6)δ10.22(s,1H),10.08(s,1H),8.65(d,1H),8.48(s,1H),7.77(d,2H), 7.64(dd,2H)7.47(s,1H),7.25(d,2H),7.15(t,2H),6.45(d,1H),3.96(s,3H),1.47(s,4H);C 28 H 22 MS (EI) of FN3O6, actual value 516.1 (MH+).

[0276] Step 4: 1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide (1) [ka]

[0277] A solution of compound 7 (300 mg, 582.0 μmol, 1 equiv.), HATU (332 mg, 873.2 μmol, 1.5 equiv.), and DIEA (301 mg, 2.3 mmol, 406 μL, 4 equiv.) in DMF (10 mL) was stirred at 6–10 °C for 1 h. Methanamine hydrochloride (79 mg, 1.2 mmol, 2.0 equiv.) was added, and the mixture was stirred at 6–10 °C for 17 h. The mixture was filtered, and the filtrate was purified by preparative HPLC (Waters Xbridge 150 mm × 25 mm × 5 μm column, gradient: 33–63% acetonitrile in 10 mM aqueous NH4HCO3, flow rate: 25 mL / min). Compound 1 was obtained (105.4 mg, 34.3% yield). 1 HNMR(400MHz,DMSO-d6)δ10.20(s,1H),10.06(s,1H),8.65(d,1H),8.61(s,1H),8.42-8.33(m,1H),7.77(d,2H),7. 68-7.61(m,2H),7.51(s,1H),7.25(d,2H),7.19-7.11(m,2H),6.46(d,1H),4.02(s,3H),2.84(d,3H)1.47(s,4H);C 29 H 25 MS(EI) of FN4O5, measured value 529.1 (MH+).

[0278] Example 1: Preparation of Fumarate Salt Form A of Compound 1

[0279] Fumaric acid (1 equivalent) in acetone was added to the free base of Compound 1 (1 equivalent), and the resulting reddish slurry was stirred at about 50° C. for 4 days. The slurry was then slowly cooled to room temperature (SC) and stirred for an additional day to give a pink slurry. The solids were then removed by positive pressure filtration to give a mixture of fumarate salt Form A and free base Form A.

[0280] Example 2: Preparation of Compound 1 Hemifumarate Salt Form A

[0281] Fumaric acid (2 equivalents) in acetone was added to the free base of Compound 1 (1 equivalent), and the resulting reddish slurry was stirred at about 50° C. for 6 days to give an off-white slurry. The solids were then removed by positive pressure filtration of the hot solution to give hemifumarate salt Form B.

[0282] Example 3: Preparation of Compound 1 HCl Form A

[0283] One equivalent of HCl was added to the free base of Compound 1 in THF, and the resulting dark red slurry was stirred at room temperature for 3 days to give a thick off-white slurry. The solids were then removed by positive pressure filtration to give HCl Form A.

[0284] Example 4: Preparation of HCl Form B of Compound 1

[0285] One equivalent of HCl was added to the free base of Compound 1 in chloroform, and the resulting reddish slurry was stirred at about 50° C. for 3 days to give a pale pink slurry. The solids were then removed by positive pressure filtration to give HCl Form B.

[0286] Example 5: Preparation of Compound 1 HCl Form C

[0287] One equivalent of HCl was added to the free base of compound 1 in methanol at a temperature of about 60°C, resulting in a yellowish slurry. The solution was then crash cooled (CC) to about -20°C and kept cold for about 2 days to give a clear orange solution. Partial fast evaporation (FE) gave a clear red solution, after which four volumes of anti-solvent MTBE were added and the solution was stirred at RT for 1 day to give compound 1 HCl Form C as an off-white solid, which was isolated by positive pressure filtration.

[0288] Example 6: Preparation of HCl Form D of Compound 1

[0289] Two equivalents of HCl were added to the free base of Compound 1 at about 50° C., and the resulting pink slurry was stirred for 5 days at 50° C. Solid Compound 1 HCl Form D was isolated by positive pressure filtration.

[0290] Example 7: Preparation of Compound 1 HCl Form A

[0291] Form A of Compound 1 is likely the most thermodynamically stable crystalline form of the free base of Compound 1. Therefore, multiple procedures can lead to the formation of this form. A list of some possible procedures for obtaining Form A of Compound 1 is provided in Table 1. This list in Table 1 is not meant to be exhaustive, and in fact, there may be many more procedures that produce this form.

[0292] [Table 5]

[0293] Example 8: Preparation of Form B of Compound 1

[0294] Compound 1 was dissolved in AcOH and crystallized by vapor diffusion (VD) using diethyl ether as an antisolvent.

[0295] Example 9: Preparation of Form C of Compound 1

[0296] Compound 1 was dissolved in HFIPA and crystallized by crash precipitation (CP) using MTBE as an antisolvent.

[0297] Example 10: Preparation of Form D of Compound 1

[0298] Compound 1 was dissolved in methanol and crystallized by crash cooling (CC). The mixture was then slurried at 2-8°C to obtain Form D.

[0299] Example 11: Preparation of Form E of Compound 1

[0300] Method A: Compound 1 was dissolved in THF and crystallized by crash cooling (CC).

[0301] Method B: Compound 1 was dissolved in 90:10 THF:water and precipitated by crash precipitation (CP).

[0302] Example 12: Preparation of Form F of Compound 1

[0303] Method A: Compound 1 was dissolved in chloroform and crystallized by slow evaporation (SE).

[0304] Method B: Compound 1 was slurried in chloroform.

[0305] Example 13: Preparation of Form G of Compound 1

[0306] Compound 1 was dissolved in chloroform and crystallized by placing the mixture in a freezer.

[0307] Example 14: Preparation of Form H of Compound 1

[0308] Form H was obtained by steam stress (VS) of amorphous Compound 1 with DCM.

[0309] Example 15: Preparation of Form K of Compound 1

[0310] Form K of Compound 1 was prepared by desolvation of Form F or Form G, which are chloroform solvates.

[0311] Example 16: Preparation of Form O of Compound 1

[0312] Form O of Compound 1 was discovered in an attempt to generate salts with different counterions in a TFE-containing solvent system and is likely a TFE solvate.

[0313] Example 17: Preparation of Phosphate Salt Form A of Compound 1

[0314] To a slurry of compound 1 in chloroform was added one molar equivalent of phosphoric acid, and the resulting mixture was then slurried for 3 days at about 50° C. The product was isolated by positive pressure filtration.

[0315] Example 18: Preparation of Form I of Compound 1

[0316] Compound 1 in a 90:10 THF / water mixture was crash precipitated with heptane and then stirred at freezing temperatures for 7 days.

[0317] Example 19: Preparation of Form J of Compound 1

[0318] Compound 1 was slurried in acetone for 14 days.

[0319] Example 20: Preparation of Form L of Compound 1

[0320] Compound 1 was slurried in chloroform for 14 days.

[0321] Example 21: Preparation of Form M of Compound 1

[0322] Compound 1 Form E was dehydrated in a vacuum oven at 77° C. for 1 day.

[0323] Example 22: Preparation of Form N of Compound 1

[0324] Compound 1 was slurried in a 70:30 mixture of TFE / MTBE at room temperature for 7 days.

[0325] Preparation Example 1: Synthesis of the hemifumarate salt of compound 1 [ka]

[0326] Synthesis of 4-chloro-7-methoxy-N-methylquinoline-6-carboxamide [ka]

[0327] To a suspension of methyl 4-chloro-7-methoxyquinoline-6-carboxylate 5 (2 g, 8 mmol) in THF (20 mL) was added methylamine in EtOH (33% w / w, 8 M, 20 mL, 160 mmol) and HO (10 mL). The resulting mixture was stirred at room temperature. The mixture became a clear solution in approximately 10 minutes and remained a clear solution throughout the reaction. Stirring was continued until the starting material was completely consumed, as evidenced by LCMS and HPLC. This took approximately 3 hours. The mixture was then concentrated, and the residue was slurried in 20 mL of water and filtered. Some EtOAc was used to transfer the material from the flask to a filter funnel. The product was dried to give 4-chloro-7-methoxy-N-methylquinoline-6-carboxamide as a white solid (yield 1.8 g, 90%, HPLC purity >97%).

[0328] Synthesis of 4-(4-aminophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide [ka]

[0329] A 5 L, three-necked round-bottom flask equipped with a thermometer, nitrogen inlet, and magnetic stirrer was charged with 4-chloro-7-methoxy-N-methylquinoline-6-carboxamide (3; 300 g; 1 equiv.), 4-aminophenol (195.9 g; 1.5 equiv.), and DMA (1500 mL). The resulting solution was stirred at room temperature, and a solution of sodium tert-pentoxide (184.52 g; 1.4 equiv.) dissolved in anhydrous THF (313 mL) was added over 5 min with stirring. The reaction mixture was heated to 75-80 °C and stirred for an additional 2-6 h. The reaction mixture was then cooled to room temperature, charged with water (3 L), and stirred for at least an additional 1 h. The product was filtered and washed twice with 600 mL of 1:1 DMA / water, followed by one 1200 mL water wash. The product was transferred to a crystallization dish and dried in a vacuum oven at 40-45°C for a minimum of 18 hours to give a light brown glossy solid (370-377g; 96-97%).

[0330] Synthesis of 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carbonyl chloride [ka]

[0331] A 250 mL three-necked round-bottom flask equipped with a thermometer, nitrogen inlet, and magnetic stirrer was charged with 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid (2, 19.11 g; 1.3 equiv.), 75 mL of anhydrous THF, and 0.25 mL of DMF (catalyst). The mixture was stirred until all solids dissolved and cooled to 5-10 °C. After this, oxalyl chloride (7.13 mL; 1.28 equiv.) was added. The resulting mixture was aged at 10-15 °C for 2-3 h, and the reaction was confirmed to be complete by in-process control (IPC). The product was used in the next step without further purification.

[0332] Alternative synthesis of 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carbonyl chloride

[0333] A 250 mL three-necked round-bottom flask equipped with a thermometer, nitrogen inlet, and magnetic stirrer was charged with 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid (2, 19.11 g; 1.3 equiv.), 75 mL of anhydrous THF, and 0.25 mL of DMF (catalyst). The mixture was stirred until all solids dissolved and then cooled to 5-15 °C. After this, oxalyl chloride (7.13 mL; 1.28 equiv.) was added. The resulting mixture was allowed to warm to room temperature and stirred for 2-4 h. The resulting product mixture was used in the next step without further purification.

[0334] Synthesis of N-(4-fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide (1) [ka]

[0335] A 500 mL three-neck round-bottom flask equipped with a thermometer, nitrogen inlet, and magnetic stirrer was charged with 4-(4-aminophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide (9, 21.3 g; 1.0 equiv.), 210 mL of anhydrous THF, and a solution consisting of potassium carbonate (27.32 g; 3 equiv.) and 100 mL of water. The additional aqueous KCO solution was rinsed in with an additional 6.4 mL of water. The vigorously stirred reaction mixture containing compound 10 from the previous example was transferred to the main reaction mixture over 30 min, maintaining the internal temperature at 20–25 °C. The transfer apparatus was rinsed with 32 mL of anhydrous THF. The reaction mixture was stirred at ambient temperature for 0.5–1 h. The resulting mixture was warmed to 35–40 °C, and the phases were allowed to separate. The lower aqueous layer was discarded, and the upper organic phase was warmed to 55-60°C, then filtered through a polish filter and rinsed with 21 mL of THF. The filtered organic phase was transferred to a 1 L three-neck round-bottom flask equipped with a thermometer, nitrogen inlet, and mechanical stirrer and charged with water at 55-60°C. The resulting solution was seeded with compound 1, and water was added to the resulting seed bed as an antisolvent over 4-4.5 hours while maintaining the temperature at 50-55°C. The resulting slurry was cooled to 20-25°C and aged for at least 2 hours. The product was then filtered, washed with water / THF, and dried.

[0336] Alternative Synthesis of N-(4-Fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide (1)

[0337] A 500 mL three-neck round-bottom flask equipped with a thermometer, nitrogen inlet, and magnetic stirrer was charged with 4-(4-aminophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide (9, 21.3 g; 1.0 equiv.), 210 mL of anhydrous THF, and a solution consisting of potassium carbonate (27.32 g; 3 equiv.) and 100 mL of water. The additional aqueous KCO solution was rinsed in with an additional 6.4 mL of water. The reaction mixture containing compound 10 from the previous example was transferred to the main reaction mixture over 0.5–1 h with vigorous stirring, maintaining the internal temperature below 27 °C. The transfer apparatus was rinsed with 32 mL of anhydrous THF. The reaction mixture was stirred at ambient temperature for 0.5–1 h. The resulting mixture was warmed to 35–40 °C, and the phases were allowed to separate. The lower aqueous layer was discarded, and the upper organic phase was warmed to 45-50°C, then filtered through a filter paper and rinsed with 21 mL of THF. The filtered organic phase was transferred to a 1 L, three-necked, round-bottom flask equipped with a thermometer, nitrogen inlet, and mechanical stirrer, and 694 mL of filtered water was added over a minimum of 1 hour. The resulting mixture was stirred at 20-25°C for a minimum of 12 hours, after which the product was filtered and rinsed twice with 42 mL of a 2:1 mixture of water:THF. The product was then dried on the filter paper at room temperature or in a vacuum oven at 40-45°C to yield a white-to-beige solid (31.36 g; 90%).

[0338] Synthesis of N-(4-fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide 1 / 2 fumaric acid (1 hemifumarate) - Method 1 [ka]

[0339] A 2000 mL three-necked round-bottom flask equipped with a thermometer, nitrogen inlet, and magnetic stirrer was charged with fumaric acid (80 g; 0.82 equiv.) and 1.2 L of 20% ethanol solution. The mixture was heated to 45–50 °C and stirred until all solids dissolved. A separate 3 L three-necked round-bottom flask equipped with a thermometer, nitrogen inlet, and mechanical stirrer was charged with N-(4-fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl))quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide (1,500 g; 1.0 equiv.). The fumaric acid solution was clarified through filter paper at 40–45 °C and transferred to the flask containing compound 1 at 40–45 °C. A 2000 mL round-bottom flask was rinsed with 300 mL of 20% water in ethanol at 45-50°C. The reaction mixture was heated to reflux (75-80°C) and stirred for 4-6 hours. The reaction mixture was then cooled to room temperature, the product was filtered, and the filter cake was washed twice with 300 mL of 20% water in ethanol. The product was then dried on the filter paper at room temperature or in a vacuum oven at 40-45°C to yield a white to beige solid (472-474 g; 97%).

[0340] Synthesis of N-(4-fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide 1 / 2 fumaric acid (1 hemifumarate) - Method 2 [ka]

[0341] Fumaric acid (2.68 g, 1 equiv.) and 1:1 EtOH / acetone (48 mL) were added to a two-piece EasyMax (EM) reaction vessel and heated to a reaction temperature of 50 °C to dissolve all material. In an adjacent EM pot, a one-piece EM vessel containing compound 1 (12.0 g, 1 equiv.) was set to a jacket temperature of 50 °C. The fumaric acid solution was transferred to the vessel containing compound 1. Seeds were added (2% seed, 0.244 g), and the vessel was heated to reflux (-65 °C). After 1 h, 0.5 mL of the slurry was filtered, washed with EtOH (6 × 1.5 mL), and analyzed by HPLC to determine the fumaric acid content (the result should be approximately 10%). The slurry was then cooled to 25 °C over 1 h and stirred for an additional 1 h. The solid was then filtered, washed with 1:1 EtOH / acetone (2 × 3 V), and dried under vacuum at 25 °C over the weekend. 1 HNMR700MHz(DMSO-d6)δ1.473(s,4H),δ4.009(s,3H),δ2.839(d,3H, 3 J 1H-1H =4.7Hz), δ2.840(d,3H, 3 J 1H-1H =4.7Hz), δ6.450(d,1H, 3 J 1H-1H =5.2Hz),δ6.632(s,2H),δ6.635(s,2H),δ7.137(m,2H),δ7.244(d,2H, 3 J 1H-1H =8.6Hz),δ7.494(s,1H),δ7.642(m,2H),δ7.776(d,2H, 3 J 1H-1H =8.6Hz),δ8.361(q,1H, 3 J 1H-1H =4.7Hz),δ8.618(s,1H),8.615(s,1H),δ8.638(d,1H, 3 J 1H-1H =5.2Hz), δ10.070(s,1H), δ10.216(s,1H), δ13.164(s,1H). 19 FNMR 700MHz (DMSO-d6; -63.72 ppm trifluoroethane reference) δ -121.460. 13C NMR700MHz(DMSO-d6)δ15.46,δ26.47,δ31.60,δ56.15,δ102.91,δ107.83,δ114.55,δ115.05(d, 2 J 19F-13C =22.2Hz),δ121.15,δ122.23,δ122.43(d, 3 J 19F-13C =7.6Hz),δ124.35,δ125.24,δ134.03,δ135.22(d, 4 J 19F-13C =2.4Hz),δ136.73,δ149.08,δ151.46,δ153.18,δ157.94,δ158.30(d, 1 J 19F-13C =240.2Hz), δ161.76, δ164.89, δ168.16, and δ168.16. 15 NNMR 700MHz (DMSO-d6) δ 106.25 ( 15 N), δ127.79( 15 N), δ128.86( 15 N), δ166.04, δ289.56( 15 N).

[0342] Pharmaceutical Composition Examples Compound 1 was designed as a solid oral tablet dosage form at 20 mg strength. The initial tablet contained 25% drug load formulation (free base equivalent). Each tablet consisted of the drug substance and a granular blend of microcrystalline cellulose, anhydrous lactose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. This tablet formulation was designated Compound 1 Pharmaceutical Composition A. Compound 1 Pharmaceutical Composition A tablets were coated with Opadry® II Blue (85F105057) (Colorcon, West Point, PA) film coating system. A list of excipients in Pharmaceutical Composition A and their functions is shown in the table below. [Table 6]

[0343] The preparation of Compound 1 Pharmaceutical Composition A tablets (20 mg) includes delumping of excipients, followed by high shear granulation, delumping of wet granules, fluid bed drying, dry milling, extragranular blending, lubrication blending, tabletting, film coating, and packaging.

[0344] Therefore, microcrystalline cellulose PH102, anhydrous lactose 60M, hydroxypropyl cellulose EXF, and croscarmellose sodium were passed through a 20 mesh screen. Compound 1 was added, and the mixture was placed in a high-shear granulation bowl and high-shear granulated with purified water. The wet granules were then passed through a Comil or sieved by hand. The wet granules were then dried using a fluidized bed dryer and passed through a Comil. The milled granules were then placed in a blender along with de-lumped colloidal silicon dioxide and croscarmellose sodium, and the mixture was blended. Then, while blending was continued, magnesium stearate (non-bovine) passed through a 30 mesh screen was added to the mixture. The lubricated blend was then compressed using an instrumented rotary tablet press. A coating suspension was then prepared by adding Opadry® II Blue to purified water to form a dispersion. The dispersion was slowly sprayed onto the core tablets loaded into a perforated pan coater. The coated tablets were packaged in child-resistant HDPE bottles with desiccant and polyester coils.

[0345] Pharmaceutical composition B of compound 1 provided an improved manufacturing process and higher manufacturing efficiency with the same drug content. In the manufacturing process of pharmaceutical composition A of compound 1, frequent shutdowns and mechanical cleaning were required due to sticking issues that could result in defective tablets. Pharmaceutical composition B of compound 1 eliminated the need for frequent shutdowns and cleaning. The sticking issue was avoided by changing the lubricant from magnesium stearate to stearic acid and increasing the binder concentration in the formulation, for example, from 3% hydroxypropyl cellulose to 5% hydroxypropyl cellulose. Thus, pharmaceutical composition B of compound 1 can be manufactured continuously, thereby increasing efficiency and meeting the demands for scale-up.

[0346] Pharmaceutical Composition B for each Compound 1 consisted of a granular blend of the drug substance and microcrystalline cellulose, anhydrous lactose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and stearic acid. Tablets were coated with Opadry® II Blue (85F105057) film coating system.

[0347] To allow for higher doses with fewer tablets, an 80 mg tablet dosage strength of Pharmaceutical Composition B was prepared. 100 mg and 120 mg tablet dosage strengths of Pharmaceutical Composition B were also prepared. Each tablet dosage strength of Pharmaceutical Composition B was prepared from a common blend and film-coated. Each tablet dosage strength was differentiated by shape, with the 20 mg and 80 mg tablets being round and oval, respectively. A list of the excipients in Pharmaceutical Composition B and their functions is provided in the table below. [Table 7]

[0348] Preparation of Compound 1 Pharmaceutical Composition B tablets (20 mg and 80 mg) consisted of de-lumping of excipients, followed by high shear granulation, de-lumping of wet granules, fluid bed drying, dry milling, extragranular blending, lubrication blending, tableting, film coating, and packaging.

[0349] Therefore, microcrystalline cellulose anhydrous PH102, anhydrous lactose, hydroxypropyl cellulose EXF, and croscarmellose sodium were passed through a 20-mesh screen. Separately, hydroxypropyl cellulose and purified water were added to prepare a binder solution. A sieved mixture of Compound 1, microcrystalline cellulose anhydrous PH102, anhydrous lactose, hydroxypropyl cellulose EXF, and croscarmellose sodium was high-shear granulated in a high-shear granulation bowl with the binder solution. The resulting wet granules were passed through a Comil or sieved by hand, dried using a fluid-bed dryer, and passed through a Comil. The milled granules were then combined with colloidal silicon dioxide and croscarmellose sodium and blended in a blender. Stearic acid passed through a 30-mesh screen was then added to the blender. The lubricated blend was then compressed using an instrumented rotary tablet press. A coating suspension was then prepared by dispersing Opadry® II Blue in purified water. The dispersion was slowly sprayed onto the core tablets loaded in a perforated pan coater. The coated tablets were packaged in child-resistant HDPE bottles with desiccant and polyester coils.

[0350] The quantitative unit compositions of Compound 1 tablets investigated, in which Compound 1 is present as the free base, including Forms A, B, C, D, D, E, F, G, H, K, O, or Q, as disclosed herein, are shown in the table below. Each composition may also contain salt forms of Compound 1, including HCl, fumaric acid, and phosphate salts, as disclosed herein, including HCl salt Forms A, B, C, and D, fumaric acid Form A, hemifumaric acid Form B, and phosphate Form A. The amount of Compound 1 salt used is adjusted to provide 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, or 120 mg of Compound 1 (free base equivalent). [Table 8] [Table 9] [Table 10] [Table 11]

[0351] stability A stability test was performed on each tablet of Pharmaceutical Composition B containing Compound 1 hemifumarate salt B. The coated tablets were packaged in child-resistant HDPE bottles with a desiccant and polyester coil. The coated tablets were subjected to long-term stability test conditions at 25°C and 60% relative humidity (RH). At the last check of 12 months, the tablets had less than 0.5% degradation of Compound 1 as hemifumarate salt Form B. The tablets were non-hygroscopic.

[0352] The coated tablets were packaged in child-resistant HDPE bottles with desiccant and polyester coils. The coated tablets were subjected to accelerated stability testing conditions at 40°C and 75% relative humidity (RH). At the last check in 6 months, the tablets had less than 0.5% degradation of Compound 1 as hemifumarate Form B.

[0353] Dissolution Each tablet of Pharmaceutical Composition B containing Compound 1 hemifumarate Form B from the stability study was subjected to dissolution testing. After 12 months of storage at 25° C. and 60% relative humidity (RH), the tablets showed greater than 50% dissolution at 5 minutes, greater than 70% dissolution at 10 minutes, greater than 85% dissolution at 20 minutes, and greater than 90% dissolution at 45 minutes. After 6 months of storage at 45° C. and 75% relative humidity (RH), the tablets showed greater than 60% dissolution at 10 minutes, greater than 90% dissolution at 30 minutes, and greater than 95% dissolution at 45, 60, and 75 minutes.

[0354] Table 8 shows the specifications of the 20 mg strength tablets after storage at 25° C. and 60% relative humidity. [Table 12]

[0355] Table 9 shows the specifications of the 20 mg strength tablets after storage at 40° C. and 75% relative humidity. [Table 13]

[0356] Other embodiments The foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many changes and modifications may be made while remaining within the spirit and scope of the invention. It will be apparent to those skilled in the art that changes and modifications may be practiced within the scope of the appended claims. It is therefore to be understood that the foregoing description is intended to be illustrative, and not restrictive.

[0357] Therefore, the scope of the present invention should be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims

1. 1. A pharmaceutical composition suitable for oral administration, comprising: a. Compound 1 having the following structure: [Case 1] or a pharma- ceutically acceptable salt thereof; b. one or more diluents; c. one or more binders; d. one or more disintegrants; e. one or more glidants; f. one or more lubricants, and optionally, g. a film coating.

2. a. Compound 1 or a pharma- ceutically acceptable salt thereof; b. one or more diluents selected from the group consisting of inorganic diluents, polysaccharides, mono- or disaccharides, or sugar alcohols; c. one or more binders selected from the group consisting of sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate (PVP / VA) copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and ethyl cellulose; d. one or more disintegrants selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, or sodium starch glycolate; e. one or more glidants; f. one or more lubricants, and optionally, g. a film coating.

3. 3. The pharmaceutical composition of claim 1 or 2, which is a capsule or tablet.

4. The pharmaceutical composition according to claim 1 or 2, which is a capsule.

5. The pharmaceutical composition according to claim 1 or 2, which is a tablet.

6. 6. The pharmaceutical composition of any one of claims 1 to 5, comprising about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, or 120 mg of Compound 1 (free base equivalent).

7. At least about 1 wt / wt%, 2 wt / wt%, 3 wt / wt%, 4 wt / wt%, 5 wt / wt%, 6 wt / wt%, 7 wt / wt%, 8 wt / wt%, 9 wt / wt%, 10 wt / wt%, 15 wt / wt%, 20 wt / wt%, 25 wt / wt%, 30 wt / wt%, 35 wt / wt%, 40 wt / wt%, 45 wt / wt%, 50 wt / wt%, 55 wt / wt%, 60 wt / wt%, 6. The pharmaceutical composition of claim 1, comprising Compound 1 in an amount of 100 w / w, 65 w / w, 70 w / w, 75 w / w, 80 w / w, 85 w / w, 90 w / w, 95 w / w, 96 w / w, 97 w / w, 98 w / w, 99 w / w, 99.5 w / w, 99.9 w / w or 100 w / w% (w / w) of Compound 1.

8. a. about 20% to about 40% by weight of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 4 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % silicon dioxide; g. about 0.5 to about 3.5% by weight of magnesium stearate, and optionally, h. a film coating.

9. a. about 20% to about 40% by weight of Compound 1; b. about 35% to about 45% by weight of microcrystalline cellulose; c. about 15 to about 25% by weight lactose; d. about 2 to about 8 weight percent hydroxypropyl cellulose; e. about 2 to about 8% by weight of croscarmellose sodium; f. about 0.1 to about 0.5 wt. % colloidal silicon dioxide; g. about 1 to about 5% by weight of stearic acid, and optionally, h. a film coating.

10. a. about 15-150 mg of Compound 1 (free base equivalent); b. microcrystalline cellulose; c. lactose; d. hydroxypropyl cellulose; e. Croscarmellose sodium, f. silicon dioxide; g. magnesium stearate or stearic acid, and optionally h. a film coating.

11. a. about 20 mg of Compound 1 (free base equivalent); b. about 30 to about 35 mg microcrystalline cellulose; c. about 15 to about 18 mg anhydrous lactose; d. about 1.5 to about 4.5 mg of hydroxypropyl cellulose; e. about 4 to about 6 mg of croscarmellose sodium; f. about 0.1 to about 0.3 mg of colloidal silicon dioxide; g. about 0.5 to about 0.7 mg magnesium stearate, and optionally, h. about 2 to about 6 mg of a film coating.

12. a. about 80 mg of Compound 1 (free base equivalent); b. about 120 to about 150 mg microcrystalline cellulose; c. about 60 to about 80 mg anhydrous lactose; d. about 6 to about 18 mg of hydroxypropyl cellulose; e. about 15 to about 25 mg of croscarmellose sodium; f. about 0.4 to about 1.5 mg colloidal silicon dioxide; g. about 2 to about 3 mg magnesium stearate, and optionally, h. about 8 to about 26 mg of a film coating.

13. a. about 20 mg of Compound 1 (free base equivalent); b. about 30 to about 40 mg microcrystalline cellulose; c. about 15 to about 20 mg anhydrous lactose; d. about 3 to about 7 mg of hydroxypropyl cellulose; e. about 3 to about 7 mg of croscarmellose sodium; f. about 0.1 to about 0.3 mg of colloidal silicon dioxide; g. about 2 to about 4 mg stearic acid, and optionally, h. about 2 to about 5 mg of a film coating.

14. a. about 40 mg of Compound 1 (free base equivalent); b. about 50 to about 70 mg microcrystalline cellulose; c. about 25 to about 35 mg anhydrous lactose; d. about 6 to about 10 mg of hydroxypropyl cellulose; e. about 6 to about 10 mg of croscarmellose sodium; f. about 0.2 to about 0.6 mg colloidal silicon dioxide; g. about 4 to about 8 mg stearic acid, and optionally, h. about 4 to about 10 mg of a film coating.

15. a. about 60 mg of Compound 1 (free base equivalent); b. about 80 to about 120 mg microcrystalline cellulose; c. about 40 to about 70 mg anhydrous lactose; d. about 12 to about 15 mg of hydroxypropyl cellulose; e. about 12 to about 15 mg of croscarmellose sodium; f. about 0.5 to about 0.8 mg colloidal silicon dioxide; g. about 6 to about 12 mg stearic acid, and optionally, h. about 6 to about 12 mg of a film coating.

16. a. about 80 mg of Compound 1 (free base equivalent); b. about 120 to about 150 mg microcrystalline cellulose; c. about 60 to about 80 mg anhydrous lactose; d. about 12 to about 30 mg of hydroxypropyl cellulose; e. about 12 to about 30 mg of croscarmellose sodium; f. about 0.5 to about 1.5 mg of colloidal silicon dioxide; g. about 8 to about 16 mg stearic acid, and optionally, h. about 8 to about 14 mg of a film coating.

17. a. about 100 mg of Compound 1 (free base equivalent); b. about 140 to about 160 mg microcrystalline cellulose; c. about 70 to about 90 mg anhydrous lactose; d. about 15 to about 25 mg of hydroxypropyl cellulose; e. about 20 to about 30 mg of croscarmellose sodium; f. about 0.8 to about 2.0 mg colloidal silicon dioxide; g. about 9 to about 18 mg stearic acid, and optionally, h. about 10 to about 30 mg of a film coating.

18. a. about 120 mg of Compound 1 (free base equivalent); b. about 165 to about 195 mg microcrystalline cellulose; c. about 80 to about 100 mg anhydrous lactose; d. about 20 to about 30 mg of hydroxypropyl cellulose; e. about 25 to about 35 mg of croscarmellose sodium; f. about 1.0 to about 2.5 mg colloidal silicon dioxide; g. about 10 to about 20 mg stearic acid, and optionally, h. about 15 to about 35 mg of a film coating.

19. The pharmaceutical composition of any one of claims 1 to 18, wherein Compound 1 is a crystalline (free base) solid or a crystalline pharma- ceutically acceptable salt.

20. 20. The pharmaceutical composition of claim 19, wherein compound 1 is a crystalline solid form selected from forms A, B, C, D, E, F, G, H, J, K, O, or Q.

21. 20. The pharmaceutical composition of claim 19, wherein compound 1 is a crystalline pharma- ceutically acceptable salt selected from the group consisting of an HCl salt of compound 1, a fumarate salt of compound 1, and a phosphate salt of compound 1.

22. 22. The pharmaceutical composition of claim 21, wherein the HCl salt of Compound 1 is selected from crystalline salt forms of HCl salt forms A, B, C, and D of Compound 1.

23. 22. The pharmaceutical composition of claim 21, wherein the fumarate salt of Compound 1 is selected from the crystalline salt forms of Fumarate Form A of Compound 1 and Hemi-Fumarate Form B of Compound 1.

24. 24. The pharmaceutical composition of claim 23, wherein the fumarate salt of compound 1 is hemifumarate salt form B of compound 1.

25. 22. The pharmaceutical composition of claim 21, wherein the phosphate form of Compound 1 is crystalline Compound 1 phosphate Form A.

26. A pharmaceutical composition according to any one of claims 1 to 25 for treating a proliferative disease or disorder in a patient in need of such treatment.

27. 27. The pharmaceutical composition of claim 26, wherein the proliferative disease or disorder is cancer.

28. 26. A process for manufacturing a tablet of the pharmaceutical composition of any one of claims 1 to 3 and 5 to 25, comprising: de-lumping excipients; granulating a mixture comprising Compound 1, the excipients, and water by high shear granulation to produce wet granules; de-lumping the wet granules; drying the wet granules in a fluid bed dryer to obtain dried granules; milling the dried granules to obtain milled granules; blending the milled granules with a disintegrant and / or a glidant to obtain blended granules; lubricating the blended granules by blending the blended granules with a lubricant to produce a lubricated blend; and compressing the lubricated blend to form a tablet.

29. 30. The process of claim 28, further comprising coating the tablet.

30. 30. The process of claim 28 or 29, wherein the disintegrant and / or the glidant is croscarmellose sodium and colloidal silicon dioxide.

31. The process according to any of claims 28 to 30, wherein the lubricant is magnesium stearate.

32. The process according to any of claims 28 to 30, wherein the lubricant is stearic acid.